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Preface
A defining feature in the biology of higher vertebrates is their extended 
and complex nervous system that allows them to rapidly integrate and process 
environmental information, control body posture, regulate homeostasis of their 
internal organs and develop complex behaviour. The principal cell types that make 
up the nervous system are the neuron and glial cell. Neurons exist in a wide range 
of different shapes but are generally built up of a soma, containing the nucleus, its 
dendritic arborisation and its single axon (Figure 1).
Figure 1- Neurons have 
a variety of shapes as 
shown in A. Schematic 
presentation of different 
ways of connection 
between neurons leading 
to diverting, converging, 
reverberating, and 
parallel alter-discharge 
circuits.
 A typical neuron potentially receives input from thousands of other neurons 
whose axons terminate on the dendrites and soma, where they form specialised 
contacts called synapses. Glial cells support neurons directly and are involved in 
every aspect of neuronal shape and function. Communication between neurons 
and their peripheral targets relies on electrical impulses that travel the length of 
the axon, a length that can be considerable (more than one meter in humans). The 
speed with which an electrical impulse travels along the length of the axon depends 
on the internal resistance of the axon. The internal resistance inversely correlates 
with axonal diameter such that larger diameter axons propagate signals faster than 
smaller axons. It is evident that evolutionary pressure, in particular in the form 
of predation, calls for nervous systems with fast conducting axons. In principle, 
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animals can increase the diameter of their axons to allow fast escape responses. A 
case in point is the squid whose giant axon can be 10 cm in length, has a diameter 
of around 1mm and conducts impulses with a very high speed. However, there is 
an obvious limit to this strategy in the form of the huge energy costs associated 
with maintaining a resting potential over the vast axonal membrane. Most larger 
animals, in particular the vertebrates, have adopted an evolutionary novelty called 
myelin. The myelin sheath is a specialized membrane structure that spirals around 
the axon and is produced by glial cells: oligodendrocytes in the central nervous 
system (CNS)  and Schwann cells in the peripheral nervous system (PNS) (Figure 
2). An important functional consequence of myelin is that axonal depolarisations 
are restricted to the nodes of Ranvier and that the capacitance of the internodal 
axonal membrane is greatly reduced. As a consequence, conductance velocities of 
myelinated axons are one to two orders of magnitude faster than non-myelinated 
axons of similar diameter. Although it is generally believed that myelin is essentially 
a vertebrate adaptation, recent studies in copepods (small marine animals; 
zooplankton) have challenged this view (Davis et al., 1999).
With this adaptation also came new vulnerabilities as instability of the 
myelin sheath through genetic or environmental causes results in demyelination 
Figure 2- (A) A myelinated axon from a peripheral nerve. Each Schwann cell wraps its 
plasma membrane concentrically around the axon to form a segment of myelin sheath 
about 1 mm long. For clarity, the layers of myelin in this drawing are not shown compacted 
together as tightly as they are in reality. (B) An electron micrograph of a section from a 
nerve. Two Schwann cells can be seen; one near to bottom is just beginning to myelinate its 
axon; the one above has formed an almost mature myelin sheath (adapted from Molecular 
Biology of the Cell (Alberts et al., 2002)).
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and eventually, if myelin is not repaired, in axonal loss causing mild to severe 
neurological problems. Prime examples of such demyelinating diseases are multiple 
sclerosis and Charcot Marie Tooth (CMT) disease. In fact, CMT is one of the most 
common inherited diseases of the nervous system with an overall prevalence of 
1 in 4000. The observation that not all axons in the vertebrate nervous system are 
myelinated, raises the question how axons are selected to become myelinated or 
not. It is generally believed that during development specific cues are presented 
by the growing axon that induce Schwann cells to ensheath, proliferate and finally 
myelinate this axon. The identity of this cue or signal is still not known. Obviously, 
gaining a detailed understanding of the molecular mechanisms that underlie myelin 
formation and maintenance will provide a rational basis for clinical strategies to 
limit axonal damage and improve nerve regeneration. The focus of our studies has 
been to dissect the transcriptional cascade of myelination in the PNS. One of the 
transcription factors implicated in regulating the myelination program is the POU 
domain transcription factor Oct-6 (also referred to in the literature as SCIP, Tst-1 or 
pou3f1). Several studies have shown that Oct-6 is the first transcription factor to be 
up-regulated prior to myelination and its expression is axonal-contact dependent 
(Arroyo et al., 1998; Scherer et al., 1994). Oct-6 appears to function largely through 
the activation of a set of genes, including the zinc-finger transcription factor Krox-
20, involved in myelination such as the major myelin genes and those involved in 
lipid metabolism (Nagarajan et al., 2001). In order to determine the exact role of 
Oct-6 in myelination, it is of importance to understand how the Oct-6 gene itself 
is regulated throughout development and regeneration. The aim of the studies 
described in this thesis was to gain insight into Schwann cell specific regulation of 
the Oct-6 gene. Given Oct-6’s central role in myelination, a detailed understanding of 
the cis-acting sequences and the regulatory pathways that converge on them might 
be of immediate importance in developing strategies to combat the debilitating 
effects of demyelinating diseases.
1.1 General structure of myelin
Myelin is a highly organized membrane structure that is wrapped around 
the axon by Schwann cells in the PNS and oligodendrocytes in the central CNS. 
The myelin sheath can be divided into compact and non-compact myelin domains 
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(Scherer and Arroyo, 2002). The organization of ‘unwrapped’ myelin is depicted 
in Figure 3. Different sets of proteins are enriched in compact and non-compacted 
domains of the myelin sheath. Compact myelin contains myelin protein zero (P-
zero), peripheral myelin protein-22 (PMP22), and myelin basic protein (MBP) 
(Scherer and Arroyo, 2002). P-zero is a type I transmembrane protein with a single 
immunoglobulin-like motif in the extracellular part and a positively charged 
intracellular part. P-zero is the most abundant protein of compact myelin (50% of 
the protein content of myelin) and plays an important role in myelin compaction 
through homophilic interactions in cis and in trans (Suter and Scherer, 2003).
 Most of the mutations found in P-zero are associated with dominantly 
inherited neuropathies with a variety of phenotypes including Charcot-Marie Tooth 
type 1B (CMT1B), Dejerine-Sottas syndrome (DSS)/congenital hypomyelinating 
neuropathies (CHN), and hereditary neuropathy with liability to pressure palsies 
(HNPP) (Suter and Scherer, 2003). 
Figure 3- A and B show the schematic 
view of a myelinated axon in the PNS 
and the proteins of myelin sheathes. 
A- One myelinating Schwann cell 
has been unrolled revealing the 
regions that form non-compact 
myelin, the incisures and paranodes. 
Adherens junctions are depicted as 
two continuous lines; these form 
a circumferential belt and are also 
found incisures. Gap junctions are 
depicted as ovals; these are found 
between the rows of adherens 
junctions. B- In the PNS, compact 
myelin sheaths contain protein zero 
(P-zero), peripheral myelin protein 
22 kDa (PMP22), and myelin basic 
protein (MBP). The non-compact 
myelin contains E-cadherin, myelin-
associated glycoprotein (MAG), 
and connexin32 (Cx32). Note that 
P-zero and MAG have extracellular 
immunoglobulin-like domains 
(semicircles), and PMP22 and Cx32 
have four transmembrane domains. 
(Adapted from Arroyo and Scherer, 
2000).
 13
PMP22 is a small trans-membrane protein and plays a structural role in 
compact myelin (Adlkofer et al., 1995). PMP22 is able to form dimers or multimers 
and interacts with P-zero (D’Urso et al., 1999; Tobler et al., 2002; Tobler et al., 1999). 
PMP22 was originally identified as the gene mutated in the natural mouse mutant 
Trembler. Two different alleles have been described for Trembler; Trembler and 
TremblerJ. Trembler and TremblerJ differ greatly in severity of the peripheral nerve 
defect reflecting the situation in human where different mutations, loss or gain of 
PMP22 alleles cause very different clinical phenotypes. In contrast to P-zero and 
PMP22, MBP is a cytoplasmic protein that mediates the fusion of the intracellular 
myelin membrane to form the major dense line. In mice with a complete deletion 
of MBP (Shiverer mice), the major dense line does not form (Kirschner and Ganser, 
1980; Rosenbluth, 1980). As the PNS is not affected in Shiverer mice, it is suggested 
that the basic cytoplasmic domain of P-zero could effectively substitute MBP 
function (Martini et al., 1995).
In addition to proteins, the myelin sheath is highly enriched in specific 
lipids , in particular cholesterol and sphingolipids (such as galactocerebroside and 
sulfatide) (Kirschning et al., 1998; Schiff and Rosenbluth, 1995).
Non-compact myelin is found as paranodal loops that fold down to contact the 
axolemma and form the paranodal septate junction. Other regions of non-compact 
myelin are the Schmidt Lanterman incisures and nodal microvilli. These regions of 
non-compact myelin are enriched in E-cadherin, MAG, DM20, Connexin32 (Cx32) 
and an uncharacterized claudin (Scherer and Arroyo, 2002).
Myelin-associated glycoprotein (MAG) is a member of the Ig super gene 
family and is a transmembrane protein present in the apical/adaxonal membrane of 
the inner mesaxon. Due to this localization, it is suggested that MAG binds molecules 
on the axonal surface and plays a role in the stabilisation of the extracellular space, 
between the inner mesaxon and the axon (Collins et al., 1997; Li et al., 1994; Sawada 
et al., 1999).
Several junctional complexes are found in non-compact myelin. The most 
numerous junctions are adherens junctions, which are located in the mesaxon 
as well as in outermost layers of the paranodal loops and incisures (Scherer and 
Arroyo, 2002). Adherens junctions contain E-cadherin, α-catenin, and β-catenin, 
and are possibly linked to the actin cytoskeleton (Fannon et al., 1995; Scherer and 
14
Chapter 1
Arroyo, 2002). Gap junctions are found between the rows of adherens junctions in 
the paranodal loops and Schmidt-Lanterman incisures. One of the gap junction 
proteins is Cx32 (GJβ1) (Bergoffen et al., 1993; Chandross et al., 1996; Scherer et al., 
1995). Dye transfer studies have provided evidence for the role of gap junctions 
in the radial transport of small molecular weight molecules across the incisures 
(Balice-Gordon et al., 1998). Mutations in Cx32 in human lead to X-linked CMT 
(CMTX) (Bergoffen et al., 1993). The pathology of this particular form of CMT is 
still poorly understood.
1.2 Glia cells in the peripheral nervous system
Different types of glia cells exist within the PNS. These types include myelin-
forming Schwann cells, nonmyelin-forming Schwann cells, teloglia of somatic motor 
nerve terminals, satellite cells that envelope neuronal cell bodies in sympathetic, 
parasympathetic and sensory ganglia, and the astrocyte-like enteric glial cells in 
the autonomous ganglia in the gut wall (Gershon, 1998; Jessen and Mirsky, 1983; 
Pannese, 1981; Robitaille, 1998). All, or almost all, of the peripheral glia cell types 
originate from the neural crest, a transient embryonic structure that gives rise to 
a wide variety of cell types in the developing embryo (Kalcheim and Le Douarin, 
1986). In addition, experiments in chicken embryos have suggested that also the 
ventral neural tube contributes to the peripheral glia population, in particular to 
Schwann cells in the ventral nerve roots (Bhattacharyya et al., 1994).
In the following paragraphs of this introduction, I will focus on the Schwann 
cell, which is the main glia cell type in the peripheral nerve trunks and the subject 
of study in this thesis. In particular, I will review how neural crest cells commit 
to Schwann cells lineage (determination) and develop to mature Schwann cells 
(differentiation).
1.3 Neural crest cells: the origin of Schwann cells
Neural crest cells delaminate from the dorsal aspect of the neural tube and 
migrate along several pathways to give rise to a wide variety of cell types.
Several stages can be defined in the ontology of the neural crest. These stages 
are: specification, delamination or migration and fate decision (Christiansen et 
al., 2000; Garcia-Castro and Bronner-Fraser, 1999). Neural crest cells are specified 
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through the interaction of surface ectoderm and neurectoderm. In addition several 
studies have suggested that also the lateral plate mesoderm plays an important 
role in neural crest formation, in specific crest precursors of the melanocytic lineage 
(Bonstein et al., 1998; Selleck and Bronner-Fraser, 1995). Although there are many 
unanswered questions about the identity of the signals involved in neural crest 
cell generation, members of the Wnt, fibroblast growth factor (FGF) and bone 
morphogenetic protein (BMP) families have been implicated (Ikeya et al., 1997; 
Liem et al., 1995; Ruffins and Bronner-Fraser, 2000). During the next phase of 
development neural crest cells emigrate form the dorsal neural tube and adopt 
mesenchymal characteristics such as their ability to migrate (delamination). What 
factors trigger this epithelial to mesenchymal transition is still unknown. However 
a number of markers have been identified that are expressed in pre-migratory crest 
cells and might be involved in this transition. These are the transcription factor 
Slug and two cadherins, c-Cad-6B and cadherin-7 (Mayor et al., 1995; Nakagawa 
and Takeichi, 1998). In addition, it has been suggested that the coordinated activity 
of Noggin and BMP4 in the dorsal neural tube triggers delamination of specified, 
slug-expressing neural crest cells (Sela-Donenfeld and Kalcheim, 1999). Once 
neural crest cells delaminate, they migrate along specific pathways and produce 
diverse cell lineages. Powerful fatemapping techniques, in particular in the chick-
quail transplantation system developed by Nicole LeDourain and colleagues, have 
allowed the identification of the diverse cell lineages that originate from the neural 
crest. (Johnston, 1966; Johnston et al., 1973; Nichols, 1981; Teillet and Le Douarin, 
1983). These fate-mapping studies demonstrated that some lineages derive from 
a specific population of crest cells originating from a discrete section along the 
neuraxis while other lineages derive from all levels of the neuraxis. For example, 
the enteric nervous system derives from the vagal crest, which originates from the 
neural tube at the level of somite 1-7. In contrast, Schwann cells originate from 
crest cells at all levels of the neuraxis (Anderson, 1997) (Figure 4A). A number of 
growth factors have been implicated in the determination of neural crest cell fate 
in vitro (Figure 4B). For instance, it has been shown that glial growth factor (GGF) 
diverts neural crest stem cells (NCSC) towards a glial fate (Shah et al., 1994), while 
transforming growth factor β (TGF-β) promotes smooth muscle cell differentiation. 
In addition, bone morphogenic proteins 2 and 4 (BMP2/4) promote differentiation 
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of autonomic neurons and to lesser extent, smooth muscle in these NCSC cultures 
(Anderson, 1997; Shah et al., 1996). The importance of these factors for neural crest 
development has been underscored by expression studies in mice (Bitgood and 
McMahon, 1995; Carraway and Burden, 1995; Millan et al., 1991). For example, 
a reduction of glial cell numbers is observed in the peripheral nerves of GGF 
knock out embryos, underscoring the importance of GGF for glial cell formation 
in the PNS. Additionally, the importance of TGF-β for cardiac crest development 
is demonstrated by heart defects in developing TGF-β knockout mice (Dickson et 
al., 1995; Meyer and Birchmeier, 1995). An assessment of the role of BMP2 and 
4 in neural crest development has been precluded by the fact that these factors 
serve essential functions at an earlier stage of embryonic development and as a 
consequence BMP2 and 4-knockout mice die early during development (Lawson 
et al., 1999; Zhang and Bradley, 1996). 
Figure 4- (A) Variations in neural crest derivatives produced at different levels along the 
rostrocaudal extent of the neuraxis. Only major subdivisions of the neuraxis and a simplified 
subset of crest derivatives are shown. The results are based primarily on fate-mapping 
experiments in avian embryos. (Adapted from Anderson, 1997). (B) Summary of instructive 
effects of growth factors on rodent neural crest cell lineage commitment in vitro. Individual 
factors that promote self-renewal of the neural crest cells have not yet been identified. The 
illustration should not be taken to imply that the three differentiated fates shown are the 
only ones available to NCSCs, not that all three fates are necessarily available to the cells at 
every division. (Adapted from Shah et al., 1994). 
 17
The neural crest represents a stem cell population that gives rise to several 
lineages depending on the local embryonic environment to which the stem cells 
are exposed. However, some of the fate-restricted neural crest precursors are able 
to change their fate by transplanting them back into younger host embryos (Le 
Douarin, 1986; Weston, 1991). These and later experiments from David Anderson’s 
laboratory gave rise to the idea that neural crest stem cells gradually undergo 
restrictions in their development. Additionally, clonal analysis of neural crest stem 
cells suggests that crest cells are heterogeneous at different stages of development, 
even at the onset of migration (Dupin et al., 1998; Liu et al., 1990). These studies 
Figure 5- Model for the segregation and reprogramming of NCC lineage as inferred from in 
vitro clonal analysis of quail NCCs. The progenitors endowed with the capacity to give rise 
to cartilage, neurons (N), glial cells (G), and melanocytes (M) have been classified according 
to the number of cell phenotypes in their progeny. Data are consist with progressive 
developmental restrictions from ‘totipotent”cells to unipotent precursors (arrows). 
Those able to yield mesectodermal cartilage cells were identified in clones derived from 
mesencephalic NC and are excluded from the trunk NC. Those able to yield mesectodermal 
cartilage cells (in yellow) were identified in clones derived from mesencephalic NC and are 
excluded from the trunk NC. The main target cells of ET3 are shown in pink. Differentiated 
glia and melanocytes could be reprogrammed by ET3 and reverse to GM bipotent NCCs. 
(Adapted from Le Douarin and Dupin, 2003).
18
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demonstrated that neural crest cells represent a true stem cell population that is 
capable of self renewal (Stemple and Anderson, 1992) (Figure 5).
Peripheral nervous system neurons and glia derive from crest cells that arise 
at different levels along the rostro-caudal axis of the neural tube. One basic and 
important question is how neural crest cells migrating in the same environment 
choose a neuronal or glia fate. Previously, Shah et al., (1996) has shown that the 
BMP2/4 promotes neuronal cell fate in neural crest stem cell cultures through 
induction of proneural bHLH transcription factors such as Neurogenin and 
Mash-1. Later studies demonstrated that bHLH transcription factors also inhibit 
gliogenesis upon activation of the Notch receptors (Morrison et al., 2000). It has 
been hypothesized that activation of Notch, through interaction with its ligands 
(Delta/Jagged) promotes glial differentiation (Morrison et al., 2000). In addition, 
early migrating neural crest cells express ErbB2, which forms a heterodimer with 
ErbB3 and transduces the signal of Neuregulin. These cells differentiate into glia 
cells in response to Neuregulin in vitro (Shah et al., 1994). Targeted deletion of ErbB3 
mice show a lack of Schwann cell precursor, further reinforcing the important role 
of Neuregulin signaling in gliogenesis (Riethmacher et al., 1997).
1.4 Schwann cell lineage and differentiation
The development of the Schwann cell lineage critically depends on the 
association of post-migratory neural crest cells with a glia fate to contact outgrowing 
axons. Most likely, the first contact between neural crest cells and axons takes place 
in the anterior part of the somites during early stages of the development (Loring 
and Erickson, 1987; Mirsky and Jessen, 1996). Recent studies have provided 
evidence for a role of neurons in diverting crest cells to the glia lineage through 
activation of the Notch pathway (Morrison et al., 2000).
As mentioned earlier, neuregulin-1 plays an important role in promoting 
the transition from neural crest cells into glia cells (Shah et al., 1994). Neuregulin-
1 has been identified in a number of experimental settings and therefore carried 
originally a number of names reflecting these different systems. Neuregulin-1 had 
been identified as the ligand of the Neu oncogene and was therefore called Neu 
differentiation factor (NDF ;a and b isoforms). Purification and identification of a 
glial growth factor resulted in the name GGF. An agent that induces acetylcholine 
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receptor expression at the neuromuscular junction was called ARIA and identified 
as neuregulin-1. In a fourth system neuregulin was identified as the activity named 
sensory and motor neuron derived factor SMDF. The neuregulin-1 gene encodes, 
through alternative splicing and promoter usage, three distinct isoforms termed 
type I, II and III (Falls et al., 1993; Garratt et al., 2000a; Ho et al., 1995; Holmes 
et al., 1992; Marchionni et al., 1993; Wen et al., 1992). All isoforms of neuregulin-
1 bind to different combinations of heterodimeric receptors of the ErbB tyrosine 
kinase receptor family. Biochemical and genetic data indicate that the functional 
Neuregulin-1 receptor in the neural crest cells and Schwann cells is the ErbB3/ErbB2 
heterodimer and that all biological effects of Neuregulin are mediated through this 
receptor (Carraway and Cantley, 1994; Ho et al., 1995; Horan et al., 1995; Meyer 
and Birchmeier, 1995; Riese et al., 1995; Riethmacher et al., 1997). Tyrosine kinase 
activity is associated with the ErbB2 protein. ErbB3 does not have kinase activity 
by itself. As already alluded to earlier, a series of in vivo studies have demonstrated 
the significance of Neuregulin signaling in Schwann cell development. Most ErbB3-
/- mice die between E11.5 and E13.5 and show lack of Schwann cells and their 
precursors (Riethmacher et al., 1997). Mice with an erbB2 null allele die before E11 
as a result of dysfunctions associated with a lack of cardiac trabeculae (Lee et al., 
1995). In addition to the cardiac phenotype, these mutant mice fail to develop neural 
crest derived cranial sensory ganglia (Lee et al., 1995; Meyer and Birchmeier, 1995). 
Rescue of the cardiac defect by crossing the transgenic erbB2 mice into an erbB2 null 
background, demonstrated a severe loss of both sensory and motor neurons and 
absence of Schwann cell precursors in the PNS (Morris et al., 1999).
Another key factor in the differentiation of neural crest cells to Schwann cells 
is the transcription factor Sox10. Sox10 expression is initiated in the neural crest 
cells as they detach from the neural tube, and its expression is maintained during 
neural crest cell migration (Britsch et al., 2001). Subsequently, Sox10 expression 
is extinguished in all neural crest derivatives except in the glial and melanocyte 
lineages. Sox10 expression in these cells overlaps with ErbB3 (Kuhlbrodt et al., 
1998a; Kuhlbrodt et al., 1998b). Analysis of Sox10 mutants has shown a lack of 
Schwann cells, like in the ErbB3 mutant animals, however the defect is more 
severe in Sox10 mutant animals as no Schwann cells are produced at all (Britsch 
et al., 2001). In Sox10 mutants, the whole peripheral glia cell population including 
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Schwann cells and satellite cells is missing from a very early developmental stage 
onwards. It has been suggested that in the absence of Sox10, the neural crest cells 
cannot differentiate to a glia cell fate (Britsch et al., 2001).
Since only a subpopulation of Sox10 expressing crest cell will adopt the glia 
fate and maintain its expression, it is suggested that Sox10 alone is not sufficient for 
the generation of glia cells and needs co-operation with additional signals (Britsch 
et al., 2001). For instance, it is possible that a specific signal can modify Sox10 in 
cells that will form glia and induce glial differentiation. Another possibility is that 
Sox10 functions synergistically with other transcription factors such as Pax3, Krox-
20, and Oct-6 to induce glial differentiation (Kuhlbrodt et al., 1998a). However, 
none of the mutations in Pax3, Krox-20 or Oct-6 affect the differentiation of neural 
crest cells into glia (Epstein et al., 1991; Franz and Kothary, 1993; Jaegle et al., 1996; 
Kuhlbrodt et al., 1998a; Topilko et al., 1994) 
One of the earliest markers expressed in glial fated neural crest cells is the 
myelin protein P-zero (Hagedorn et al., 1999; Lee et al., 1997). These P-zero positive 
Schwann cell precursors are further defined by expression of a number of additional 
markers and growth and survival requirements. These cells can first be identified 
in he embryonic nerve trunks at day 12-13 of gestation in the mouse or day 14-15 
in the rat. Schwann cell precursors differentiate around E14-15 (mouse; E17 rat) 
into bi-potential immature Schwann cells, which subsequently differentiate into 
either myelin forming or non-myelin forming Schwann cells found in the mature 
nerve. These main transitions, from neural crest cells to Schwann cell precursors, 
from precursor to immature Schwann cells and finally the formation of the two 
mature Schwann cell types, are identified based on their antigenic properties and 
survival abilities in vitro (Jessen and Mirsky, 1999). Some of these main differences 
are shown in Table 1. In the developing nerve, ongoing proliferation of Schwann 
cell precursors and immature Schwann cells invasion of the axon bundles followed 
by radial sorting of individual axonal fibers and families of small fibers results in 
the establishment of separate axon-Schwann cell units. Each of these units consists 
of a large number of axons enclosed by a family of Schwann cells (Martin and 
Webster, 1973; Webster et al., 1973). The number of axons per unit falls gradually as 
Schwann cells continue to proliferate because some axons degenerate.
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Migrating crest cells Schwann cell precursors Immature Schwann cells
β-Neuregulin-1 does not 
promote survivalb
β-Neuregulin-1 promotes 
survivalc
β-Neuregulin-1 promotes 
survivald
P0 negative
d,e P0 positive
e P0 positive
PMP22 negativee PMP22 positivee
PLP negativef PLP positivef
GAP-43 negative GAP-43 positive
CD9 negativef CD9 positivef
B-FABP negativeh B-FABP positiveh
Desert Hedgehog RNA 
negative Desert Hedgehog RNA positive
i Desert Hedgehog RNA 
positivei
Die by apoptosis when removed 
from axons and plated in vitro 
(absence of autocrine loops) g, k
Full survival under same 
conditions due to presence of 
autocrine loopsg, k
Cytoplasmic S100 negativeg Cytoplasmic S100 negativeg Cytoplasmic S100 positiveg
No mitogenic response to FGF in 
rat j, c, l
Mitogenic response to FGF 
in rat j, c, l
Flattened with extensive cell-cell 
contacts in vitrog Bi- or tri-polar in vitro
g
O4 antigene negativec, m O4 antigene negativec, m O4 antigene positivec, m
GFAP negativen GFAP negativen GFAP positiven
High motilityg High motilityg Low motilityg
Table 1 - Some of the main differences between migrating crest cells, Schwann cell precursors 
and immature Schwann cells (adapted from (Jessen and Mirsky, 1999)). a- Migrating crest 
refers to crest cells in vivo that are on a level with the dorsal third of the neural tube. b- (Shah 
et al., 1994); c- (Dong et al., 1995); d- (Stewart et al., 1996); d- (Lee et al., 1997); e- (Hagedorn et 
al., 1999); f- Unpublished observation (Brennan, Calle, Mirsky, and Jessen); g- (Jessen et al., 
1994); h- (Britsch et al., 2001); i- (Parmantier et al., 1999); j- in mouse FGF is a mitogen under 
identical condition. k- (Meier et al., 1999); l- (Dong et al., 1999); m- At present, this has been 
thoroughly tested in the mouse. n- (Jessen et al., 1990).
Finally, the Schwann cell reaches a 1:1 ratio with one of axons, elongates along the 
axon and exits the cell cycle. These cells are referred to as promyelin stage Schwann 
cells (Figure 6). Around birth, most of the myelin-competent Schwann cells are at the 
pro-myelin stage and assemble basal lamina around the axon. Final differentiation 
or maturation of Schwann cells consists of wrapping of Schwann cell membrane 
around the axon in a process referred to as myelination. This process of myelin 
formation requires major cellular adaptations in gene expression and metabolism 
to allow the formation of specialized Schwann cell-axon structures at the node and 
internode, Schmidt Lanterman incisures and compaction of the myelin sheath. The 
mature non-myelinating Schwann cell appears later than myelin forming Schwann 
cells (Jessen and Mirsky, 1991). In general, non-myelinating Schwann cells ensheath 
a number of axons with a diameter smaller than 1 µm (Friede, 1972). There are 
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some similarities between molecular markers of non-myelinating Schwann cells 
and immature Schwann cells, such as GFAP and NGF receptors (Jessen and Mirsky, 
1991).
1.5 Schwann cell and nerve interactions
Reciprocal interactions between axon and Schwann cells are important for 
the generation of the peripheral nerves. Not only Schwann cells rely on neuron-
derived signals during development, in particular Neuregulin-1, but neurons also 
depend for their survival to a large extent on Schwann cell derived factors. This is 
especially true at early stages before axons have innervated their peripheral targets. 
In the following sections, I will briefly review some of these interactions. 
Figure 6- Schwann cell differentiation. Schwann cells originate in the neural crest (A) and 
migrate along the axons to the periphery. Before myelination, each Schwann cell surrounds 
multiple small axons (B). Myelination is preceded by Schwann cell division (C). One daughter 
cell isolates a single axon (D) and myelinates it (D’), while the other surrounds developing 
axons (E) and continues to divide (C) until all appropriate axons are myelinated. Many small 
diameter axons are not myelinated and are ensheated by non-myelinated Schwann cells (F). 
(Adapted from Lazzarini et al., 2004).
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1.5.1 Schwann cell precursors are dependent on axonal survival factors
It has been known for a long time that direct axonal contact stimulates 
proliferation of Schwann cell precursors (Salzer et al., 1980). It was also shown 
that glia growth factor (GGF), an isoform of Neuregulin-1, is able to prevent 
apoptotic death of Schwann cells in vivo (Trachtenberg and Thompson, 1996). 
These data suggest that direct contact is necessary for the survival of Schwann 
cells. The ErbB3 null mutation and rescue of erbB2 mice have given direct genetic 
evidence for the role of Neuregelin-1 in Schwann cell precursor maintanance, 
proliferation, and differentiation as I discussed in the previous section (Morris 
et al., 1999; Riethmacher et al., 1997; Woldeyesus et al., 1999). Further, analysis 
of the erbB2 conditional knockout mouse using a krox20-cre allele has shown a 
widespread peripheral neuropathy characterized by abnormally thin myelin 
sheaths, containing fewer myelin wraps (Garratt et al., 2000b). This study 
demonstrates that Neuregulin-1, in addition to its role in establishing the Schwann 
cell precursor, also plays a role in myelination. These results indicate a role for 
Neuregulin-1 signaling during myelination of Schwann cells. Thus, Neuregulin-
1 signaling has different roles during different developmental stages of Schwann 
cells. A recent study demonstrated a role for Neuregulin-1 signaling in regulating 
myelin thickness (Michailov et al., 2004). In particular, it was shown that reduction 
in the Neuregulin-1 gene dosage is sufficient to decrease myelin thickness, whereas 
no effect on myelin thickness was observed in the ErbB2+/- animals. Additionally, 
overexpression of type III Neuregulin-1 in transgenic mice (under control of the 
neuron-specific Thy1 promoter) induces hypermyelination. Therefore, Michailov 
and colleagues (2004) have suggested that axonal Neuregulin-1 represents at 
least one of the surface molecules regulating the amount of myelin wrapping by 
myelinating Schwann cells.
1.5.2 Schwann cells are the source of neurotrophic factors
Schwann cells release neurotrophic factors that are important for the survival 
of neurons (Jessen and Mirsky, 1999). Mice targeted for erbB3 and rescued for 
Erb2-/- showed the loss of most sensory and motor neurons besides the loss of 
Schwann cell precursors (Morris et al., 1999; Riethmacher et al., 1997; Woldeyesus 
et al., 1999). The loss of neurons is not due to ablation of Neuregulin signaling 
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in these cells since ErbB3 is not expressed in motor neurons and is found only 
in a subset of cells in dorsal root ganglia (Meyer et al., 1997; Riethmacher et al., 
1997). Examination of the number of neurons in these animals indicates that 
neurons are generated in normal numbers at first, but are gradually lost during 
embryonic development. In addition, absence of neuronal degeneration in erbB3-/- 
and chimeric mice indicates that the loss of neurons in erbB3-/- is indirect and is due 
to the absence of Schwann cells (Riethmacher et al., 1997). The role of Schwann cell 
precursors in supporting the survival of developing neurons was also evident in 
a study of targeted Sox10 mice, since these mice also lack Schwann cell precursors 
and show death of DRG and motor neurons (Britsch et al., 2001). It was reported 
that Schwann cells in vitro and in vivo express a variety of neurotrophic factors, 
including CNTF, GDNF, BDNF, LIF, PDGF, FGFs, NT3, TGF-β or IGF. Expression of 
these factors support maintenance of the sensory and motor neurons (Bunge, 1993; 
Jessen and Mirsky, 1999). In particular, these factors are strongly upregulated in 
denervated Schwann cells following nerve transection or damage and might thus 
contribute to nerve regeneration.
1.5.3 The organization of the myelinated nerve fiber
The reciprocal interaction between Schwann cell and axon directs the 
organization of the myelinated fiber in distinct domains. These domains include 
the nodes of Ranvier, the paranodal junction, the juxtaparanodes and the 
internodal regions, which all consist of a glial and an axonal component (Poliak 
and Peles, 2003) (Figure 7). The nodes of Ranvier are periodic interruptions of the 
myelin sheath with an interval of about 100 times the axon diameter. This nodal 
gap is filled with microvilli extended by the outer layer of Schwann cells and is 
ensheathed by a basal lamina. The nodal axolemma is characterized by a very high 
density of voltage-gated Na+ channels and other transmembrane and cytoskeletal 
proteins, including the cell-adhesion molecules (CAMs) of the immunoglobulin 
(Ig) superfamily, Nrcam and neurofascin-186 (Nf186), the cytoskeletal adaptor 
ankyrin G and the actin-binding protein spectrin βIV (Berghs et al., 2000; Davis et 
al., 1996; Kordeli et al., 1995; Poliak and Peles, 2003). Recent studies have revealed 
the presence of two K+ channels, Kv3.1 and Kcnq2, in the nodal membrane (Devaux 
et al., 2003; Devaux et al., 2004). Paranodal junctions are located at both sides of 
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the nodes of Ranvier and are formed by the lateral sides of Schwann cell sheaths 
At paranodes, the axonal membrane contains a complex of two cell-adhesion 
molecules, contactin-associated protein (Casper) and contactin, which are essential 
for the generation of the axoglial junction (Poliak and Peles, 2003). Absence of these 
proteins at paranodal junctions results in the disappearance of septa junctions and 
a widening of the space between axon and the paranodal loops (Boyle et al., 2001; 
Poliak and Peles, 2003). The zones just beyond the paranodal junctions are called 
juxtaparanodes. Juxtaparanodes are the location of heteromultimers of the delayed 
rectifier K+ channels of the shaker family, Kv1.1, Kv1.2, and Kvβ2, which are mainly 
present in the small axons in a complex with Casper2 (Poliak et al., 1999; Rasband 
et al., 1999; Rhodes et al., 1997; Wang et al., 1993).
One of the interesting issues in the formation of the axoglial apparatus is 
how different compartments are established within this superstructure. Several 
lines of evidence have indicated that during development, the positioning of Na+ 
channels at the node of Ranvier is directed by Schwann cells. During myelination, 
Na+ channels are expressed at the moving edge of the developing myelin sheaths 
and as two neighboring Schwann cells approach each other, the two hemi-nodal 
Figure 7- Schematic longitudinal cut 
of a myelinated fibre around the node 
of Ranvier showing a heminode. 
The node, paranode, juxtaparanode 
(JXP) and internode are labelled. The 
node is contacted by Schwann cells 
microvilli in the PNS. Myelinated 
fibers in the PNS are covered by a 
basal lamina. The paranodal loops 
form a septate-like junction (SpJ) 
with the axon. The internode extends 
from the juxtaparanodes and lies 
under the compact myelin. (Adapted 
from Poliak and Peles, 2003). 
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structures fuse to form the mature node (Poliak and Peles, 2003; Vabnick et al., 
1996). It has been speculated that a boundary macromolecular sieve composed 
of the neuronal and glial transmembrane proteins bound to the cytoskeleton of 
both axons and myelinating cells exists. This macromolecular sieve possibly is 
involved in clustering of Na+ channels when they are collected and moved as a 
group toward the future nodes (Pedraza et al., 2001). The importance of the myelin 
sheath in clustering the Na+ channels is further underscored by the observation that 
demyelination leads to disruption of Na+ clusters and spreading of channels over the 
demyelinated axonal membrane, which in turn, may lead to an axonal conductance 
block (Vabnick et al., 1996). In addition, during myelination potassium channels 
of the shaker type are excluded from the nodal axolemma and cluster in the juxta-
paranodal region under the compact myelin (Scherer and Arroyo, 2002; Vabnick 
et al., 1999). Although the importance of myelin formation for the organization 
of the axolemma and clustering of the channels in their appropriate domains is 
undisputed, several studies have suggested that in the CNS axonal domains are 
established through induction of a soluble factor in the absence of oligodendrocytes. 
This factor is not produced by Schwann cells. However, the presence of some 
sodium channel clustering in dystrophic mice suggest that myelin independent 
mechanisms of axonal domain organization might play a role in the PNS as well 
(Deerinck et al., 1997; Kaplan et al., 1997). Additionally, it has been suggested that 
axoglial contact in the CNS also plays a role in the developmental switch of Na+ 
channel isoforms in the nodes (Ishibashi et al., 2003; Rios et al., 2003; Ulzheimer et 
al., 2004). Although it is not completely clear what mechanisms operate to organize 
axonal domains, it is important to keep in mind that glia cells have a big impact on 
the distinct domains on the axolemma.
1.5.4 The role of myelinating Schwann cells on regulating axonal structure and 
neurofilament phosphorylation
It has long been known that myelinating Schwann cell influence the radial 
growth of axons (de Waegh et al., 1992). Study of nerves from Trembler mice with a 
defect in peripheral myelin protein 22 kDa (PMP-22), have shown three interesting 
points: first, clear reduction in average axonal caliber (de Waegh and Brady, 1990), 
second, increase in the axonal cytoskeletal elements (Low, 1976) and third decrease 
in axonal transport velocities (de Waegh and Brady, 1990). Grafting experiments 
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have indicated that these changes are spatially restricted to axon segments 
without normal myelination and are not observed in adjacent regions with normal 
myelination (de Waegh and Brady, 1990). Genetic studies have gathered adequate 
evidence for the role of neurofilament in determination of axonal diameter in 
myelinated regions (Eyer and Peterson, 1994; Jacomy et al., 1999; Ohara et al., 
1993; Zhu et al., 1997). Neurofilaments are heteropolymeric intermediate filaments 
composed of neurofilament light (NF-L), medium (NF-M), and heavy (NF-H) 
chain subunits (Lee et al., 1986). It is suggested that neurofilament phosphorylation 
is essential for proper axonal diameter, which is regulated by Schwann cells (de 
Waegh and Brady, 1990; Yin et al., 1998). A recent study has demonstrated that the 
COOH-terminal tail domain of NF-M is an essential target for myelin-dependent 
axonal radial expansion (Garcia et al., 2003). It has been suggested that myelin-
associated glycoprotein (MAG) plays a role in mediating the Schwann cell signal to 
the axon through the low affinity nerve growth factor receptor p75NTR in association 
with neuronal gangliosides GT1b and GD1a (Tcherpakov et al., 2002; Wang et 
al., 2002; Wong et al., 2002; Yamashita et al., 2002). In vivo support for the role of 
MAG dependent signaling in determining axonal caliber through neurofilament 
phosphorylation comes from two studies. First, peripheral nerves of MAG-deficient 
mice show a reduction in neurofilament phosphorylation, interfilament spacing, 
and internodal axonal caliber (Yin et al., 1998). Second, patients with anti-MAG 
demyelinating peripheral neuropathy show a significantly reduced axonal caliber 
(Lunn et al., 2002).
1.5.5 Formation of the perineurium
A protective epithelial sheath that is composed of two layers surrounds 
peripheral nerves. These two layers, called the perineurium and the epineurium 
respectively, surround the endoneurial compartment that contains the axons, 
Schwann cells, bloodvessels and resident macrophages. The peri- and epineural 
sheaths protect nerves and act as nerve-tissue barriers (Bunge et al., 1989; Olsson, 
1990). It has been shown that Schwann cells induce the formation of perineural sheath 
cells by secreting Desert Hedgehog, a member of the Hedgehog family of signaling 
molecules (Parmantier et al., 1999). Desert Hedgehog expression can be detected 
in developing nerves around E11.5 by cRNA in situ hybridization, while mRNA 
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expression of the hedgehog receptor Patched can be detected in the mesenchyme 
immediately around the nerve at E15.5 (Parmantier et al., 1999). Study of the 
peripheral nerves in dhh-/- mice has shown a severely abnormal perineurium and 
epineurium, which are thin and patchy and permeable to proteins and migratory 
cells, In addition, perineural cells have abnormal tight junctions and fail to express 
connexin43 (Parmantier et al., 1999). These results demonstrate that Schwann cells 
do not only interact with neurons, but also play a role in the development of tight 
junctions of connective tissue sheaths of the nerves. However, it has been suggested 
that other signals than Desert Hedgehog are involved in the initial recruitment of 
mesenchymal cells around the peripheral nerve, since the generation of these cells 
in the peripheral nerves of Dhh null mice is not affected (Parmantier et al., 1999; 
Salzer, 1999). 
1.5.6 Myelination
While it is well accepted that myelination by Schwann cells is controlled 
by axonal contact associated signals, the nature of these signals has remained 
largely uncharacterized (Mirsky and Jessen, 1999). It has been suggested that the 
neurotrophins, including BDNF and NT3, are important components of these 
signals. The neurotrophins BDNF and NT3 exert opposite effects on myelination 
in Schwann cells/dorsal root ganglia neuron co-cultures (Chan et al., 2001) (Figure 
8). While BDNF appears to stimulate myelination, NT3 acts as an inhibitor of 
myelination in these cultures. Additionally, injection of NT3 in the developing 
sciatic nerve of newborn animals inhibits myelin formation while BDNF stimulates 
myelination (Chan et al., 2001). Neurotrophins act through the Trk family (TrkA, 
TrkB and TrkC) of tyrosine kinase receptors and the neurotrophin receptor 
p75NTR . Several isoforms of TrkB and TrkC receptors exist which are generated 
through alternative splicing. Recently, Cosgaya and colleagues have suggested that 
p75NTR, TrkB-T1 (an isoform of the TrkB receptor), and full-length TrkC receptors 
are the main mediators of neurotrophin signaling in PNS myelination (Cosgaya et 
al., 2002). They propose that activation of TrkC during proliferation, elongation and 
ensheathment of Schwann cells prevents inappropriate activation of the myelination 
program. At the time that myelination is initiated, NT3 expression levels drop 
releasing the inhibitory effect of NT3. In addition, they suggest that p75NTR is the 
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functional receptor for BDNF, enhancing myelination in developing Schwann cells. 
The myelination process is ended by removing the extracellular BDNF through 
binding to the TrkB-T1 receptor, which functions as a decoy, and later through 
down-regulation of the neurotrophins and their receptors. Interestingly, p75NTR-/- 
knock out mice show a reduction of ≥50% in myelinated axons, which persists into 
adulthood (Lee et al., 1992). 
A series of in vitro studies have suggested the involvement of cyclic AMP 
and the PKA pathway in Schwann cell proliferation and differentiation. Elevating 
intracellular cAMP levels in proliferating cells (through the reversible adenyl 
cyclase activator forskolin or dibutyryl camp) potentiates the mitogenic response of 
Figure 8- Actions of endogenous neurotrophins and their receptors throughout myelination. 
During glial proliferation, elongation, and ensheathment, NT3 levels decrease whereas TrkC 
and p75NTR remain constant. The activation of TrkC by NT3 during these phases prevents the 
myelination program from proceeding. When myelination is initiated, NT3 protein levels 
have already become undetectable, thereby removing its inhibitory action. At the same time, 
BDNF acts as a positive modulator of myelination through the activation of p75NTR. Once 
active myelination is under way, extracellular BDNF is removed through its binding to the 
increased levels of TrkB-T1. After myelination is complete, all the neurotrophins and their 
receptors are down-regulated. (Adapted from Cosgaya et al., 2002).
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Schwann cells to growth factors, including neuregulins, fibroblast growth factors, 
platelet-derived growth factors, insulin-like growth factors, and TGF-βs (Dong et 
al., 1997). Additionally, it is possible to promote differentiation of Schwann cells by 
using forskolin or other cAMP elevating reagents in absence of serum (Dong et al., 
1997; Morgan et al., 1991). Several myelin related genes are upregulated in cultured 
Schwann cells following administration of forskolin. These genes include the 
myelin genes P-zero, MBP, P2, PMP-22, and connexin 32 (Lemke and Chao, 1988; 
Monuki et al., 1989; Scherer et al., 1995; Suter et al., 1994). Furthermore, forskolin 
induces expression of the Oct-6 and Krox-20 transcription factors and down-
regulates AP1. Oct-6 and Krox-20 are expressed in promyelinating Schwann cells 
(Monuki et al., 1989; Zorick and Lemke, 1996). Therefore, cAMP might function as 
a second messenger of an axonal signal(s) that promote myelination (Bermingham 
et al., 2001). Recently, it was shown that the NF-κβ signaling pathway also plays 
a role in myelinating Schwann cells. It was found that NF-κβ is up-regulated in 
Schwann cell precursors and treatment of Schwann cell/dorsal root ganglia neuron 
co-cultures with inhibitors of NF-κβ leads to a differentiation arrest before Schwann 
cells have established a 1:1 ratio with axons (Nickols et al., 2003). In addition, knock 
out DRG cultures from the p65-/- subunits of NF-κβ show a myelin deficiency in 
comparison to DRG explants derived from heterozygote and wild type littermates. 
Interestingly, inhibition of NF-κβ in cultured Schwann cells abolishes Oct-6 gene 
expression, suggesting a role for NF-κβ in regulating Oct-6 expression (Nickols 
et al., 2003). Oct-6 plays an important role in the timely onset of myelination in 
Schwann cells. These data suggest that the NF-κβ pathway is essential for PNS 
myelination, including regulation of Oct-6 gene regulation. 
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1.6 Transcriptional control of cellular differentiation
Multicellular organisms develop from one single cell, the fertilized egg. 
During embryonic development, this cell divides and gives rise to a great diversity 
of different cell types. The progression of cellular differentiation requires the 
differential recruitment of genetic information encoded within the base sequence 
of DNA in the chromosomes of the cell (the genome). The expression of this 
genetic information is regulated at multiple levels and involves the generation of a 
RNA intermediate, mRNA, which is translated by the ribosomes into protein. An 
important regulatory decision is made at the level of initiation of transcription, the 
process by which the DNA sequence is transcribed by RNA polymerase into an 
RNA intermediate. Three different RNA polymerases exist in eukaryotic cells, each 
involved in the transcription of different sets of genes. RNA polymerase II transcribes 
protein-encoding genes, while RNA polymerase I and III transcribe ribosomal RNA 
genes and tRNA genes respectively. In contrast with prokaryotic polymerases, 
eukaryotic RNA polymerases do not bind directly to the DNA but are recruited to 
promoter sequences through interaction with DNA binding proteins or protein-
complexes. In addition, the compaction of eukaryotic DNA into highly condensed 
chromatin fibers represents a major barrier for the transcription apparatus. Thus, 
in global terms, temporal cell-type specific expression of a particular gene requires 
a mechanism for overcoming this repressive barrier selectively and activation of 
the RNA polymerase containing complex that assembles at the gene promoter. 
Over the last decade it has become evident that chemical modifications of amino 
acids in histone proteins dramatically change the overall structure of the chromatin 
fiber and that these modifications correlate with gene activity. Such modifications 
include acetylation, methylation, phosphorylation, ubiquination and sumoylation 
of lysine, serine and arginine residues in the N-terminal tail of histone proteins (see 
for a recent review (Felsenfeld and Groudine, 2003)). Local chromatin remodeling 
is brought about by a host of enzymatic activities (histone acetylases, deacetylases, 
methylases) that are targeted to specific domains through interaction with 
sequence specific DNA binding proteins. Two important classes of DNA sequences 
can be distinguished within a gene locus. One is the gene promoter, which is 
operationally defined as the site at which the pre-initiation complex, including the 
RNA polymerase, assembles (see box). 
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Box-1 Basal transcription by RNA polymerase II
Transcription from a naked DNA template in the absence of regulatory 
elements is referred to as basal transcription. A polymerase II preinitiation 
complex (PIC) is assembled at the promoter of class II genes in a stepwise 
process. However, this process may never occur in vivo in the absence of the 
regulatory elements. The first step in the assembly is binding of the TATA box-
binding protein (TBP) to the TATA box of pol II promoters. The majority of TBP 
present in a cell is associated with TBP associated factors (TAFs). This complex 
of TBP with TAFs that binds to the pol II promoters is called TFIID and contains 
at least eight TAFs with a cumulative mass of about 750 kDa. It has been shown 
that TFIID is also essential for transcription of TATA-less promoters and that 
recombinant TBP alone is not sufficient for directing transcription from TATA-
less promoter containing initiator elements [Pugh and Tjian, 1990; Smale et al., 
1990]. Later, it was shown that TFIID is able to bind to the initiator elements of 
both TATA-containing and TATA-less promoters [Kaufmann and Smale, 1994; 
Purnell and Gilmour, 1993].
After binding of TBP to DNA, TFIIA binds directly to TBP and stabilizes its 
interaction with DNA. Next, TBP bound to DNA creates a binding site for TFIIB. 
TFIIB itself serves as a platform for TFIIF and polymerase II (pol II), which are 
present in a complex. The next two factors bound to pol II are TFIIE and TFIIH and 
finally this mega dalton complex is able to initiate transcription. The description 
of assembly of the pol II complex in here is very generalized. It is important 
to keep in mind that the eukaryotic transcription machinery is very complex 
and that eukaryotic promoters are very divers. Given these complexities, there 
are different mechanisms involved in transcription regulation in different steps 
including at the chromatin level. Some of the components of the pol II complex 
are very conserved from yeast to human.
The second class of sequences modulates the rate of transcription from the 
promoter through several distinct mechanisms. These sequences include upstream 
promoter elements, enhancers, silencers and locus control regions. All these DNA 
elements can be bound by sequence specific DNA binding proteins including 
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transcription factors and their accessory factors, to affect local chromatin structure 
and transcription initiation.
1.7 Regulatory elements involved in gene expression
In general, gene expression is controlled by multiple regulatory sequences 
that are usually distributed at a variable distance from the gene promoter. A 
gene might have different regulatory elements, which contribute individually 
or cooperatively to expression of the gene in a temporal and/or cell-type specific 
fashion. These regulatory elements consist of different types of sequences including 
promoter elements, insulators, Locus Control Regions (LCR), and enhancers. In 
the following paragraphs, I will briefly discuss what is known in general about 
regulatory sequences, the proteins they bind and how they affect the transcriptional 
output of a gene.
A gene promoter is usually thought to consist of two elements: The core 
promoter and the promoter-proximal regions. Core promoters are the site of 
transcription initiation and spread from –40 to +40 nucleotides relative to the 
transcription start site. Several DNA sequence motifs can be identified within core 
promoters including the TATA box, initiator (Inr), TFIIB recognition element (BRE), 
and down stream core promoter element (DPE) (Butler and Kadonaga, 2002). The 
promoter-proximal region is located immediately upstream of the core promoter 
and consists of binding sites for transcription factors such as SP1 and CTF (CCAAT-
binding transcription factor).
In general, enhancers are regulatory elements that can be located, at a 
considerable distance, either upstream or downstream of the transcription initiation 
site and in either orientation. Schaffner and colleagues first described enhancers 
in the early 1980s. They demonstrated that a 72bp tandemly repeated sequence 
upstream of the late viral promoter in the SV40 genome is capable of increasing 
the transcriptional output of a linked rabbit beta-globin gene (Banerji et al., 1981). 
Binding of specific combinations (dictated by the specific sequence of the enhancer) 
of ubiquitous and signal or cell specific transcription factors results in enhanced 
expression from the linked promoter. Enhancers consist of a number of transcription 
factor binding motifs and assembly of transcription factors on the enhancer leads 
to the formation of a nucleoprotein complex referred to as the “enhanceosome” 
34
Chapter 1
(Carey, 1998; Grosschedl, 1995; Kim and Maniatis, 1997). The assembly of the 
enhanceosome is dependent on the concentration of the relevant activators in a cell 
and their ability to engage in combinatorial interactions; subthreshold concentration, 
or altered positioning on the DNA prohibit cooperative binding (Carey, 1998). The 
binding of transcription factors to the enhancer is often cooperative; meaning 
that they promote the binding of each other and to DNA in a three-dimensional 
structure and this cooperativity results in “synergy” (Carey, 1998). The synergistic 
effect arises from an increase of the total free energy, translated into stability of 
the complex. In addition, assembly is a dynamic process as demonstrated for the 
formation of the interferon-β enhanceosome (IFNβ) (Munshi et al., 1998; Yie et al., 
1999). Some prototypical enhanceosomes have been studied in detail, including 
those of the T-cell receptor α (TCRα) and interferon-β genes (Giese et al., 1995; 
Kim and Maniatis, 1997, Mayall et al., 1997; Merika et al., 1998). The enhancesome 
of IFNβ consists of the transcription factors NF-κB (p50 and p65 subunits), IRF-1, 
ATF-2, c-Jun, and HMG I. The enhanceosome of TCRα include a lymphoid-specific 
HMG-domain protein (LEF-1), Ets-1, AML-1 (CBFα2, PEB2αB), and ATF or CREB 
bind to TCRα (Carey, 1998). The presence of architectural proteins such as LEF-1 
and HMG I in these nucleoprotein complexes is of special interest. These proteins 
exhibit sequence-specific DNA-bending properties and belong to the larger family 
of chromatin-associated high mobility group (HMG) proteins. Some of these 
proteins play a role in cooperativety and synergy. For example HMG I (HMGA1) 
facilitates binding of NF-κB to the INF-β enhancer by inducing a bend in the DNA. 
LEF-1 belongs to another class of HMG proteins and, unlike HMG I, has a context-
dependent activation domain. Specific binding of LEF-1 induces DNA bending 
allowing all the other transcription factors (AML-1, ETS, ATF, and CREB) assemble 
on the enhancer (Hernandez-Munain et al., 1998).
Several studies have shown that the enhanceosome directly interacts with 
the basal transcription machinery, in particular with TFIID, TFIIA, and the USA 
cofactor, resulting in the synergistic recruitment of TFIIB to the promoter (Kim et al., 
1998). The communication between the regulatory elements and promoter appears 
reciprocal. The enhanceosome recruits the pol II machinery, but the machinery 
reciprocally facilitates assembly of the enhanceosome (Carey, 1998; Kingston et al., 
1996). Nevertheless, it is still a matter of debate how exactly enhancer-promoter 
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communication is established. Several models have been proposed to explain 
long distance gene activation by the enhancer. Most of these models explain some 
aspects of enhancer-promoter communication but not others and there is no direct 
evidence available to distinguish between them. The three most compelling models 
are referred to as the looping model, the tracking or scanning model, and the 
accessibility (linking) model. The looping model proposes the direct interaction 
between enhancer-promoter by formation of a DNA loop (Ptashne and Gann, 
1997). The tracking or scanning model proposes that all the regulatory elements 
first assemble on the enhancer and then slide along the DNA until they reach the 
linked promoter. In the accessibility model, the recruitment of facilitator proteins 
to the enhancer modifies the entire chromatin domain between the enhancer and 
promoter and makes formation of higher order complexes along the chromatin 
fiber possible. Several recent studies have provided new evidence for the tracking 
and the looping model. Two different studies, employing different experimental 
approaches have shown direct interactions between enhancer and promoter in 
the β−globin locus (Carter et al., 2002; Tolhuis et al., 2002). However, Hatzis and 
Talianidis (2002) provided experimental evidence for a dynamic mechanism in 
HNF-4α enhancer-promoter communication such as suggested in the tracking 
model (Blackwood and Kadonaga, 1998).
1.8 POU domain transcription factors
The focus of research in this thesis is the role and regulation of the 
transcription factors Oct-6 and Brn-2. These proteins belong to the POU domain 
family of transcription factors. I will first review what is known about this family of 
proteins and then discuss the role of Oct-6 and Brn-2 in Schwann cell development. 
The review is further extended to include additional transcription factors known to 
be important for Schwann cell development and myelination.
The POU domain was originally identified as a region of high homology 
within the mammalian transcription factors Pit-1, Oct-1, Oct-2 and in the nematode 
unc-86 (Herr et al., 1988). The POU domain, which constitutes the DNA binding 
domain of these proteins, consists of a ~60 amino acid long homeo domain (the 
POU-homeodomain) connected by a short linker sequence (15-27 amino acids) to 
an amino terminal POU specific domain of ~75 amino acids (Ryan and Rosenfeld, 
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1997). More than 14 POU genes have been found in the human genome and they 
have been classified into six groups based on the amino acid sequence of their POU 
domains and on conservation of the variable linker region (Ryan and Rosenfeld, 
1997; Wegner et al., 1993). A summary of expression patterns of different classes of 
POU proteins, in addition to their different names, is shown in table 3.
These transcription factors contribute to controlled gene expression and 
provide a cell type-specific pattern of gene expression during different stages of 
development. Most POU proteins show a spatially progressive expression 
POU factor Species Expression Function
Embryo Adult
Class I
POU1F1= Pit-1/ 
GHF1
rodent/ human neural tube, 
pituitary
pituitary survival of three pituitary cell types
Class II
POU2F1= Oct-1
frog/ chicken/ 
rodent/ human
high in mid-/ 
forebrain anterior 
neural crest
ubiquitos gastrulation, apoptosis
POU2F2= Oct-2/ 
OTF-2 rodent/ human neural tube
lymphoid 
cells, nervous 
system
proliferation of 
maturing B-cells
POU2F3= Oct11/ 
Skn-1/Xlnr116/21 frog/ rodent epidermis thymus, testis
Pdm-1= dPOU19/ 
nubbin fruit fly
neuroectoderm, 
sensory organs
none
segmentation, 
specification of 
neural identity, 
wing patterning
Pdm2= dPOU28/ 
miti-mere fruit fly
neuroectoderm, 
sensory organs
none
segmentation,spec
ification of neural 
identity
ceh-18 nematode muscle, epidermis
gonadal 
sheath cells
oocyte cell cycle 
arrest, gonad 
migration, 
epidermal 
differentiation
Class III
POU3F1= Oct-
6/ Tst-1/ SCIP/ 
XIPOU1/ zp-50
zebrafish/ frog/ 
rodent/ human
ES cells, nervous 
system, skin
brain, testis, 
retina,
Schwann cells
Schwann cell 
differentiation, 
myelination, 
respiration
POU3F2= Brn-2/ 
N-Oct-3/XIPOU3
frog/ rodent/ 
human nervous system
brain/
Schwann cells
neural induction, 
development of 
hyothalamus
POU3F3= Brn-1/ 
ZfPOU1
zebrafish/ rodent 
/ human
nervous system, 
kidney
brain
POU3F4= Brn-4/ 
RHS2/ XIPOU2
frog/ rodent/ 
human nervous system brain
neural induction, 
sense of hearing
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cfla= drifter/ 
ventral veinless fruit fly
trachea, epidermis, 
midline glia 
neurons, wing disc
migration of 
tracheal cells 
and midline glia, 
development of 
wings veins
ceh-6 nematode
Class IV
POU4F1= Brn-3/ 
Brn-3.0/ Brn-3A/ 
RDC-1
rodent/ human sensory neurons, 
pituitary
brain
neurite 
outgrowth, 
coordination, 
suckling
POU4F2= Brn3.2/ 
Brn-3B rodent/ human
sensory neurons, 
retina, 
brain
development of 
retinal ganglion 
cells
POU4F3= Brn3.1/ 
Brn-3C/ XBrn3
zebrafish/ frog/ 
rodent/ human sensory neurons
development 
of hair cells in 
the inner ear
I-POU fruit fly
ganglia, ventral 
nerve code 
supraoesophageal
unc-86 nematode neural lineage neural cells
specification of 
neural identity
Class V
POU5F1= Oct-3/ 
Oct-4/ OTF-3/ 
OTF-4
rodent/ human
ES/ EC cells, 
primordial germ 
cells
ovary, testis pluripotency
sprm-1 rodent male germ cells
pou2 zebrafish blastomeres, 
epiblast, hindbrain
gastrulation
Oct-25 Frog gastrula oocytes (low)
Oct-60= XIPOU91 Frog
Blastula, gastrula: 
mesoderm, 
ectoderm
oocytes
Oct-91= XLPOU91 Frog gastrula oocytes
Class VI
POU6F1= Brn-5/ 
POU[C]/ Emb/ 
mPOU/TCFβ1/
zebrafish /
rodent/ human
widespread high in 
nervous system
ubiquitous
RBF-1 rodent/ human retina, midbrain, 
spinal cord
retina,
medhabenula, 
hypothalamus
Table 2 - Classes of the POU domain genes and their expression sites and function. Adapted 
from (Veenstra et al., 1997). Systematic designation and frequently used names are listed. 
pattern early in development while later in development they are restricted to 
distinct patterns (He et al., 1989). Even Oct-1, a protein that is expressed in every 
cell-type and tissue tested (Scholer et al., 1989; Staudt et al., 1986; Sturm et al., 
1988), is subject to differential regulation (Hsu and Chen-Kiang, 1993; Veenstra et 
al., 1995). Veenstra et al., (1995) observed differential expression of Oct-1 RNA and 
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protein in ectodermal and mesodermal cell lineages of Xenoups embryos. During 
later stages of development, Oct-1 expression becomes restricted to specific brain 
structures and cranial neural crest derivatives. Based on these results, it has been 
suggested that Oct-1 plays a role in the specification and differentiation of neuronal 
and neural crest cells (Veenstra et al., 1995).
One important way in which the activity of a transcription factor can be 
regulated is by sequestration in the cytoplasm. The maternally inherited Oct-1 is 
retained in the cytoplasm during early development, and gradually translocates 
to the nucleus around the mid-blastula transition (Veenstra et al., 1999). Another 
example is the Oct-6 protein, which is expressed, in different cerebral and 
hippocampal subpopulations. It is reported that the Oct-6 expression profile changes 
with developmental time (postnatal) such that by postnatal week 28 expression is 
exclusively cytoplasmic before it finally disappears two weeks later at postnatal 
week 30 (Ilia et al., 2003). Posttranslational modifications of POU factors, such as 
phosphorylation and acetylation, are also known to play a role in regulating DNA 
binding activity or dimerization with other transcription factors (Augustijn et al., 
2002; Caelles et al., 1995; Tanaka and Herr, 1990).
As can be concluded from the expression patterns summarized in Table 2, 
many POU factors are expressed in overlapping patterns during development. 
Additionally, some of these factors have a similar DNA-binding preferences 
suggesting functional redundancy. This was shown for Oct-1 and OCA-B in Oct-
2 deficient B cells, Brn-1 and Brn-2 genes in cortical neuron development and 
recently in class III factors Oct-6 and Brn-2 in Schwann cell differentiation (Jaegle 
et al., 2003; Luo and Roeder, 1995; McEvilly et al., 2002; Sugitani et al., 2002). It was 
demonstrated that mPOU binds the octamer motif (ATTTGCAT) and other POU 
protein target sites. Another possibility for generating a cell type-specific pattern 
of gene expression is the interaction between POU proteins. For example Pit-1 and 
Oct-1/ mPOU (Fumoto et al., 2003) or with transcription factors from other families 
such as vitamin D receptors, N-CoR, and GATA-2 through the homeodomain of Pit-
1 (Augustijn et al., 2002). This results in either synergistic activation or repression 
of the target genes (Veenstra et al., 1997). 
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1.9 POU domain factors in development of the nervous system
Many of the known mammalian POU domain genes are expressed in 
the nervous and the neuroendocrine system. The only member of class I, Pit-1, 
is expressed from E14.5 onwards in the caudomedial region of the pituitary 
gland. In the adult Pit-1 regulates expression of the genes for growth hormone 
(GH), prolactin (PRL), growth hormone-releasing hormone (GHRH receptor), and 
thyroid hormone receptor beta type 2 (TSHβ) in three distinct cell types of the 
anterior pituitary gland; somatotropic, lactotropic, and thyrotropic cells (Rhodes 
et al., 1994). Pit-1 gene expression in the pituitary is maintained, at least in part, 
through a positive feedback loop that involves Pit-1 binding to its own promoter 
and to a distal enhancer (DiMattia et al., 1997; Rhodes et al., 1993). The study of 
mice homozygous for the Snell allele (a Pit-1 point mutation) or a Pit-1 null allele 
revealed that Pit-1 is necessary for the differentiation and survival of TSH-positive 
cells (Lin et al., 1994). Similarly, dominant and recessive mutations in Pit-1 were 
identified in human pituitary diseases (Cushman et al., 2002).
Oct-1 and Oct-2 were among the first POU proteins identified and both 
proteins belong to sub-class II. As stated earlier Oct-1 is expressed in every cell-
type examined. Oct-1 has been implicated in gonadotropin-releasing hormone (GnRH) 
and vasoactive intestinal peptid (VIP) gene regulation and in silencing of the TSHβ 
gene (Eraly and Mellon, 1995; Kim et al., 1996; Rostene, 1984). Oct-2 is prominently 
expressed in B-lymphocytes, as well as in the developing and adult nervous system 
(He et al., 1989; Stoykova et al., 1992). The Oct-2 gene is subject to alternative splicing 
and produces at least eight different transcripts (Wirth et al., 1991). Several studies 
have demonstrated that the different splice variants are expressed in different 
cell types and it has been suggested that the Oct-2 proteins encoded by the splice 
variants exercise different functions (Lillycrop and Latchman, 1992; Stoykova et 
al., 1992). Evidence from in vitro studies has suggested that the splice variants Oct-
2.4 and Oct-2.5 act as repressors in neuronal cells, while the predominant form 
in the B cells, Oct-2.1, has a stimulatory effect (Lillycrop and Latchman, 1992). 
Oct-2 null mice develop normally but die shortly after birth (Corcoran et al., 
1993). Unexpectedly, disruption of Oct-2 has no effect on the B cell development. 
However, B-cell maturation is disturbed in the absence of Oct-2 (Corcoran and 
Karvelas, 1994; Schubart et al., 2001). Although no gross structural abnormalities 
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were observed in the nervous system, it is suggested that functional defects in the 
nervous system cause the early postnatal death of Oct-2 mutant animals (Corcoran 
et al., 1993; Ninkina et al., 1995). 
Class III POU factors were first identified through a PCR-based cloning 
strategy and were shown to be expressed widely in the developing nervous system 
(He et al., 1989). Expression of Brn-1, Brn-2, and Brn-4 is detectable from E10 in the 
nervous system and in the primitive endocrine hypothalamus adjacent to the third 
ventricle (He et al., 1989). At E14, Brn-2 and Brn-4 are colocalized in the developing 
paraventricular (PVN) and supraoptic nucleus (SON) regions. In addition Brn-4 is 
expressed in the potential precursors of the anterior hypothalamus. Further, Brn-1 
is expressed dorsolaterally in the presumptive zona incerta and in a dorsoventral 
stripe lateral to Brn-4 expressing cells (Alvarez-Bolado et al., 1995; Andersen and 
Rosenfeld, 2001). In general, Brn-1 and Brn-2 show a different spatial expression 
pattern at the early stages of development, but an overlapped expression pattern in 
the adult brain. Brn-4 is widely expressed during development, but becomes more 
restricted in the adult (Alvarez-Bolado et al., 1995). Oct-6 exhibits very restricted 
expression early in the developing embryo, in particular the nervous system but 
its expression expands greatly at later stages of development (Alvarez-Bolado 
et al., 1995; Zwart et al., 1996). Homozygous deletion of the Oct-6 gene causes 
developmental abnormalities in the nervous system. In particular, development 
of the phrenic nucleus in the brain stem appears affected. As the phrenic nerve 
innervates the diaphragm it has been suggested that developmental defects in this 
brain-stem nucleus underlies the high early postnatal mortality in Oct-6 mutant 
animals (Bermingham et al., 1996). Additionally, Oct-6 is expressed in other 
nuclei involved in breathing rhythm and airway movement including the nucleus 
ambiguous, the nucleus tractus solitarius, and the glossopharyngeal nucleus. 
Furthermore, Oct-6 is expressed in the Schwann cell lineage of the PNS, which will 
be discussed later.
It has been suggested that class III POU factors play a role in defining 
different regions in the developing brain (Alvarez-Bolado et al., 1995). For example 
Brn-2 knock out mice show dramatic abnormalities in the hypothalamic/posterior 
pituitary gland and die before P6 (Nakai et al., 1995; Schonemann et al., 1995). 
Severely reduced neuronal cell numbers in the PVN and SON of the Brn-2 null mice 
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suggest a role in proliferation or survival of these neurons. In addition, decreased 
vasopressin and oxytocin expression levels suggest a role for Brn-2 in cell specific 
regulation of these neuropeptides (Nakai et al., 1995). Deletion of the Brn-4 gene in 
mice causes deafness in mice due to several developmental defects in the inner ear. 
No abnormalities in brain development were observed in Brn-4 mutant animals. 
Furthermore, it has been shown that mutations in Brn-4 cause non-sensory deafness 
in humans (de Kok et al., 1995; Minowa et al., 1999; Phippard et al., 1999). Brn-3a 
(Brn-3.0), Brn3-b (Brn-3.2), and Brn-3c (Brn-3.1, POU4F3) make up the subclass IV 
(Gerrero et al., 1993; Lillycrop et al., 1992). Expression studies of these factors imply 
a role for them in neuronal differentiation. Knock-out mice were generated for each 
of these factors. While Brn-3a null mice show widespread loss of the sensory and 
motor neurons and die directly after birth (McEvilly et al., 1996; Xiang et al., 1996), 
mice lacking Brn-3b and Brn-3c are viable and show loss of retinal neurons (Brn-
3b), leading to blindness, or vestibular neurons (Brn-3c) in the inner ear leading to 
deafness (Erkman et al., 1996). It is suggested that differences in the phenotypes of 
class IV knockouts reflect their expression pattern during development and in the 
adult brain (Latchman, 1999; Ninkina et al., 1993; Turner et al., 1994). 
The class VI POU protein Brn-5 is expressed in the developing and adult brain 
and some organs outside the nervous system, including kidney, lung, and testis 
(Andersen et al., 1993). Brn-5 is prominently expressed in post-mitotic neurons, 
suggesting a role in terminal neuronal differentiation (Cui and Bulleit, 1998).
1.10 Transcription factors involved in Schwann cell differentiation
As stated in previous sections, continued interactions between neuronal and 
Schwann cells is essential for the development of the peripheral nerve tissue. In order 
to understand the signaling cascades that regulate Schwann cell differentiation, we 
need to identify the transcription factors involved in this differentiation process. 
Moreover, we need to understand how these transcription factors are regulated 
during Schwann cell differentiation. In the next section I will discuss a number 
of transcription factors that have been implicated in Schwann cell differentiation 
(Figure 9).
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1.10.1 Pax-3
During embryogenesis, Pax-3 expression is detectable from embryonic day 
8.5 in the small number of cells located in the dorsal region of the neural groove 
and in the neural tube (Kioussi and Gruss, 1996). Pax-3 expression continues in 
the neural crest cells at the craniofacial level in the spinal ganglia of the mouse 
(Goulding et al., 1993). At E12.5, Pax3 expression is observed in Schwann cell 
precursors that populate the embryonic peripheral nerves (Kioussi and Gruss, 
1996). Kioussi and colleagues (1995) reported that Pax-3 expression is down 
regulated after E12.5 in proliferating Schwann cells until E18.5 (around birth in 
mouse) and re-expressed in terminally differentiating Schwann cells. After birth, 
Pax-3 expression is down-regulated in myelinating Schwann cells, but is maintained 
in non-myelinating Schwann cells. In contrast to these results, another group has 
reported continuous expression of Pax-3 in the sciatic nerve during Schwann cell 
proliferation (E12.5-E18.5) by RT-PCR (Blanchard et al., 1996). Due to the lack 
of in situ or immnuohistochemistry analysis, these data are not clear. It is also 
important to note that a significant number of neural crest-like cells and Schwann 
cell precursors are present in a developing nerve (Morrison et al., 1999), which 
possibly affected the results of Pax-3 expression in developing nerve.
Figure 9- Transcription factor expression profile during Schwann cell development. P-zero 
is shown as a marker for myelination. 
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Pax-3 acts as a repressor of myelin genes including P-zero and MBP and as an 
activator of non-myelinating markers including p75, the low affinity neurotrophin 
receptor by co-transfection studies in culture (Kioussi et al., 1995). It might be 
concluded from these results that Pax-3 is involved in fate decision between non-
myelinating and myelinating Schwann cells.
The early role of Pax-3 in generating Schwann cell precursors is suggested by 
study of natural mutants splotch (sp) and a milder form splotch delayed (spd) in mice. 
splotch mice die around E13.5 and sp around E18.5 due to abnormalities in neural 
crest derived tissues in which Pax-3 is normally expressed including Schwann cell 
precursors (Epstein et al., 1991). The peripheral nerves of sp mice lack Schwann 
cells while spd mice have reduced numbers of Schwann cells (Franz, 1990; Moase 
and Trasler, 1990). In human, homozygous mutation in Pax-3 results in a clinical 
condition referred to as Waardenburg syndrome (Waardenburg, 1951).
1.10.2 SOX10
This transcription factor belongs to the large family of high mobility group 
proteins, containing a DNA-binding domain named as HMG domain (Laudet et 
al., 1993). The Sox protein family constitutes a subgroup among the high mobility 
group proteins as they show highest similarity (more than 50%) to the HMG box 
of the testis-determining gene SRY (Sry box; sox) (Wegner, 1999). Sox proteins are 
divided into seven subgroups (A to G groups) (Wegner, 1999). Sox10 is a member of 
group E and is expressed in neural crest cells and some of its derivatives including 
Schwann cells (Kuhlbrodt et al., 1998a). Sox10 expression is maintained during 
all the Schwann cell development stages and is not completely down-regulated 
after Schwann cell differentiation. In the CNS, Sox10 expression is detectable in 
the oligodendrocyte precursors and later in mature oligodendrocytes (Kuhlbrodt 
et al., 1998a). 
The spontaneous mouse mutant Dominant megacolon (Dom) was shown to 
carry a mutation in Sox10 (Herbarth et al., 1998; Southard-Smith et al., 1998). In 
this mutant allele, a frame shift gives rise to a non-functional protein (Herbarth et 
al., 1998). Homozygous Dom mice die before embryonic day 13 and show a loss of 
neurons and glia cells in the PNS and lack of the enteric nervous system (resulting 
in the megacolon phenotype) (Herbarth et al., 1998; Southard-Smith et al., 1998). 
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Mutations in Sox10 have also been identified in patients with Shah-Waardenburg 
syndrome and Hirschsprung disease. In both of these diseases, the clinical 
phenotype results from a loss of neural crest derivatives (Herbarth et al., 1998; 
Southard-Smith et al., 1998). In mice with Sox10 homozygously deleted, the whole 
population of peripheral glia cells are missing, including satellite cells, suggesting 
a role for Sox10 in glia cell fate decisions (Britsch et al., 2001). 
It has been demonstrated that Sox10 functions synergistically with Oct-6 
as a strong transcriptional activator of promoters containing adjacent Oct-6 and 
Sox10 binding sites (Kuhlbrodt et al., 1998a). Interestingly, this synergistic function 
is specific to Oct-6 since Brn-1, closely related to Oct-6, is not able to cooperate with 
Sox10. Another example of synergistic function of Sox and POU proteins is between 
Sox2 and Oct3/4 on the FGF-4 enhancer (Yuan et al., 1995). Therefore, Sox10 not 
only plays a role in glia fate decisions but probably also during differentiation of 
these cells.
1.10.3 Transcription factor AP1
The Activator Protein (AP) is a hetero-dimeric transcription factor family 
that participates in the regulation of a variety of cellular processes including 
proliferation, differentiation, and apoptosis (Chinenov and Kerppola, 2001). AP1 
can be composed of several combinations of basic-region-leucine zipper (bZIP) 
proteins that belong to the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1 and 
Fra-2), Maf (MafB, MafA, MafG/F/K and Nrl) and ATF (ATF2, LRF1/ATF3, B-ATF, 
JDP1, JDP2) transcription factor families These dimeric proteins bind to the 12-
O-tetradecanoylphorbol-13-acetate (TPA) response element (5’-TGAG/CTCA-3) or 
the cAMP response elements (CRE, 5’-TGACGTCA-3’) (Shaulian and Karin, 2002). 
Previously it was demonstrated that c-Jun expression levels drop in Schwann 
cells during myelination in vivo and after induction of differentiation by cAMP 
in vitro (Awatramani et al., 2002; De Felipe and Hunt, 1994; Monuki et al., 1989; 
Shy et al., 1996; Stewart, 1995). Prior to initiation of myelination, Schwann cells 
exit the cell cycle and become resistant to developmental death signals such as 
TGF-β. (Brown and Asbury, 1981; Friede and Samorajski, 1968; Stewart et al., 1993). 
TGF-β is implicated as a death signal in developing nerves, where it is believed 
to induce apoptosis in nonmyelinating cells, sparing cells expressing myelin 
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proteins (Parkinson et al., 2001). Later studies demonstrated that activated c-Jun 
(phosphorylation at serine-63) acts as a key downstream event in TGFβ-induced 
Schwann cell death (Parkinson et al., 2001). 
Recently, Parkinson and colleagues showed that TGF-β death signals are 
inactivated through Krox-20, protecting cells from death trigger by growth factor 
deprivation (Parkinson et al., 2004). Furthermore, they showed that constitutive 
expression of Krox-20 in cultured Schwann cells results in down-regulation of the 
JNK-c-Jun pathway and prevents activation of this pathway by NRG-1 and TGF-β. 
It therefore appears the anti-proliferative function of Krox-20 is mediated through 
down-regulation of phosphorylated and unphosphorylated c-Jun protein and 
phosphorylated JNK (Parkinson et al., 2004). Interestingly, Krox-20-/- Schwann cells 
show a high rate of DNA synthesis and apoptosis during postnatal development 
(Topilko et al., 1994; Zorick et al., 1999). This phenotype could be explained by 
alteration of Krox-20 dependent cell autonomous responses to proliferative (NRG-
1) and apoptotic (TGF-β) signals (Parkinson et al., 2004).
1.10.4 The POU domain transcription factor Oct-6
Oct-6, also known as POU3f1, Tst-1, and SCIP, belongs to subclass III of the 
POU domain transcription factor family (see Table 2) (Herr et al., 1988; Meijer et 
al., 1990; Suzuki et al., 1990). The Oct-6 gene is located on the distal part of mouse 
chromosome 4 and on the short arm of the human chromosome 1 and consists, 
like the other members of this subclass, of a single exon (Avraham et al., 1993; 
Kuhn et al., 1991; Xia et al., 1993). This led to the suggestion that this subclass arose 
during evolution through a retroposon event in an early vertebrate ancestor (Hara 
et al., 1992; Kuhn et al., 1991). Indeed, the single class III genes in the genomes of 
Drosophila and C elegans do contain introns (NCBI database). The four class III POU 
genes are not genetically linked. Therefore, the extensive overlap in expression 
patterns of these genes must be the result of independent acquisition of regulatory 
elements at the site of integration or from common regulatory sequences associated 
with the transposed mRNA precursor (Alvarez-Bolado et al., 1995; Suzuki et al., 
1990; Zwart et al., 1996). 
In the Schwann cell lineage, Oct-6 expression is first observed in Schwann 
cell precursors at embryonic day 12 (E12). Oct-6 expression is greatly increased 
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in promyelinating Schwann cells and is then rapidly down-regulated once cells 
have initiated myelination (Arroyo et al., 1998; Blanchard et al., 1996; Scherer et al., 
1994). 
In cultured primary Schwann cells, Oct-6 expression is rapidly up-regulated 
after treating cells with an intracellular cAMP elevating agent, such as forskolin. In 
addition, cAMP stimulation in cultured cells leads to expression of myelin related 
genes including P-zero and P2 (Monuki et al., 1989). These results have suggested 
a role for Oct-6 in activating myelin genes (Monuki et al., 1989). However, co-
transfection studies in rat Schwann cells, using a P-zero promoter driven reporter 
construct and an Oct-6 expression cassette, suggested that Oct-6 represses myelin 
gene expression. (Monuki et al., 1993; Monuki et al., 1990). The repressive function 
of Oct-6 was shown to be associated with the amino-terminal domain of Oct-6. 
Repression of the P-zero promoter was not abolished by mutating all of the potential 
Oct-6 binding sites suggesting that Oct-6 represses this promoter indirectly, through 
titrating out a positive acting factor (squelching). However, the repressive function 
of Oct-6 was negated by a truncated form of Oct-6 (essentially consisting of the 
POU domain) (Monuki et al., 1993) These and other results led to assumption that 
interacting factors or adaptor molecules modulate the activity of Oct-6 in a cell type 
and promoter context-specific fashion (Meijer et al., 1992; Monuki et al., 1993).
In contrast to what was expected on the basis of these transfection experiments, 
Oct-6 knock out studies suggest that Oct-6 functions as a positive regulator of the 
promyelin to myelinating transition in Schwann cells. Mice homozygous for the 
mutated Oct-6 allele are born at normal Mendelian ratios but most of them die 
shortly after birth. A small percentage of Oct-6-/- mice (2-4%) survives for a longer 
period. These mice are smaller than their heterozygous littermates and exhibit 
occasional tremors in the second postnatal week (Bermingham et al., 1996; Jaegle et 
al., 1996). The high postnatal mortality in Oct-6 mutant animals has been attributed 
to respiratory distress and disorganization of the phrenic nucleus. Oct-6 is highly 
expressed in different parts of the brain, involved in breathing regulation, including 
the phrenic nucleus, the nucleus tractus solitarius, and the nucleus ambiguous. 
Apart from CNS defects, Oct-6 knock out animals demonstrate a transient arrest 
of Schwann cell development at the promyelin stage in the PNS (Bermingham et 
al., 1996; Jaegle et al., 1996). Microscopic examination of Oct-6 mutant nerves at 
 47
Figure 10- (A) Electron microscopic sections of Scitic nerves of p4 and p16 Oct-6 DSCE/βgeo. (B) 
Quantification of the promyelin-myelinating transition in percentages. The transition of the 
promyelin-myelinating transition is shown in wildtypes, Oct-6DSCE/+, and Oct-6DSCE/βgeo during 
days of postnatal development. 
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postnatal day 1 show normal numbers of Schwann cells at the sorting and promyelin 
stage of differentiation. However, during the first week of postnatal development 
most Oct-6 mutant Schwann cells arrest at the promyelin stage of differentiation. 
In contrast, wild type or heterozygous Schwann cells progress to the myelinating 
phase during this period. Only during the second and third postnatal week do 
Oct-6 mutant Schwann cells initiate myelination. Thus Oct-6 appears required in 
promyelin Schwann cells to initiate myelination (Figure 10) (Jaegle et al., 1996). It 
has been suggested that down-regulation of Oct-6 in myelinating cells also depends 
on Oct-6. This suggestion is based on experiments, where the β-galactosidase gene 
expression was introduced into the Oct-6 locus and showed as a marker for Oct-6 
during different developmental stages (Bermingham et al., 1996; Jaegle et al., 1996). 
While expression of β-galactosidase is completely lost in the adult nerve of Oct-
6+/- animals, Oct-6 knock out animals still express β-galactosidase after completing 
myelination (Jaegle and Meijer, 1998). This result suggests that the Oct-6 locus is 
not down-regulated in the Oct-6-/- nerves. Thus Oct-6 itself is needed for this down- 
regulation. 
The fact that Schwann cells, in the absence of Oct-6, do eventually initiate 
myelination suggested that an Oct-6 redundant factor exist in Schwann cells. 
Recently, such a factor (Brn-2) has been identified which is a member of the POU 
class III family (Jaegle et al., 2003). The Brn-2 expression pattern in Schwann cells 
is very similar to Oct-6. In Oct-6 deficient nerve, Brn-2 expression is normally up-
regulated as in wild type nerves but the peak of expression is protracted. Brn-2 
is down-regulated once myelination in Oct-6 mutant animals starts. In summary, 
Oct-6 gene expression in Schwann cells is under the control of axonal signals 
and possibly Oct-6 in turn regulates expression of down-stream genes involved 
in myelination, including Krox-20 (Ghislain et al., 2002; Topilko, 2001). Once 
myelination is underway, Oct-6 acts as a repressor by down-regulating its own 
expression (Jaegle and Meijer, 1998). It has been suggested that this functional 
change results from interaction of Oct-6 with different partners. 
To uncover the identity of axonal signals regulating Oct-6 gene expression, 
it is needed to understand how Oct-6 gene expression is regulated. Recently, 
we identified a Schwann cell specific regulatory element within the Oct-6 locus 
(Mandemakers et al., 2000). This element is sufficient to drive the temporally correct 
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expression of a reporter gene or of Oct-6 in the Schwann cell lineage of transgenic 
mice. 
1.10.5 Zinc finger transcription factors
Krox-24 (Egr-1) and Krox-20 (Egr-2) belong to the zinc finger transcription 
factor family also known as Egr (early growth response factor). All members of 
this family have a highly conserved DNA-binding domain consisting of three zinc 
finger motifs. Each motif binds to three nucleotides of a nine base pair GC-rich DNA 
element (Pavletich and Pabo, 1991). Krox-20 is involved in hindbrain segmentation, 
bone formation and Schwann cell development. Most Krox-20 mutant animals die 
shortly after birth although some survive for up to two weeks (Levi et al., 1996; 
Schneider-Maunoury et al., 1993; Swiatek and Gridley, 1993; Topilko et al., 1994). 
Krox-24 is involved in pituitary development where it has a direct role in regulation 
of the luteinizing hormone β-subunit. Krox-24-/- animals show growth defect and 
both sexes are sterile due to severe pituitary dysfunction. Despite the fact that Krox-
24 is expressed in Schwann cells, no developmental defects were observed in this 
cell lineage. (Lee et al., 1996; Topilko et al., 1998). Study of the Krox-24 expression 
pattern, using a β-galactosidase knock in reporter gene, revealed that Krox-24 is 
expressed in Schwann cell precursors from embryonic day 10.5 (E10.5) until E14.5 
in both cranial and spinal nerves (Topilko et al., 1997). Krox-20 expression is also 
reported around E10.5 but it is restricted to a small glial cell population close to 
the neural tube. These cells form the CNS/PNS boundary and are usually referred 
to as boundary cap cells. Around E15.5, Krox-24 expression is down regulated 
while Krox-20 expression becomes activated (Topilko et al., 1997). In a mature 
myelinated peripheral nerve, Krox-20 is expressed in the myelinated Schwann cells 
while Krox-24 expression is restricted to non-myelinating Schwann cells. During 
degeneration/regeneration, such as in a nerve lesion experiment, Schwann cells 
dedifferentiate distal to the site of lesion and after removal of myelin and cell debris 
(Wallerian degeneration), associate to regenerate axons and differentiate once 
more. It has been reported that several marker genes for mature myelinating cells, 
including Krox-20, are rapidly down-regulated while marker genes for immature 
Schwann cell, such as Krox-24, are up-regulated (Topilko et al., 1997). Although 
it has been suggested that the switch from Krox-24 to Krox-20 may regulate the 
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transition from Schwann cell precursor to immature Schwann cell, there is no 
direct evidence for such a role (Topilko et al., 1997). In the mouse, transition from 
Schwann cell precursor to immature Schwann cell happens around E14-E15 and 
in the absence of Krox-24 this transition still occurs. Further, in Krox-24 mutant 
animals no Schwann cell abnormalities are reported (Lee et al., 1996; Topilko et al., 
1998). Krox-20-/- animals have shown a clear role for Krox-20 in transition from the 
promyelinating to myelinating Schwann cells (Topilko et al., 1994). In the absence 
of Krox-20, Schwann cells show a permanent arrest at the promyelin stage in which 
Schwann cells establish a 1:1 ratio and ensheath axons but do not form a myelin 
sheath (Topilko et al., 1994). Examination of promyelin Schwann cells of Krox-20-
/- nerves at p12 showed high proliferation as well as apoptosis still resulting in a 
normal number of Schwann cells in comparison to wild type nerve (Zorick et al., 
1999). Oct-6 expression does not diminish in the peripheral nerve of the Krox-20 
mutants and these mutants show a severe reduction in myelin protein expression, 
including P0, MBP, and PMP22 (Topilko et al., 1994). It is also suggested that the 
high expression of Oct-6 in the Krox-20 knock out nerve causes the high proliferation 
rate of promyelinating Schwann cells. Besides proliferation, the increase in 
apoptosis is explained by competition for limited axon-associated survival signals, 
which is in disagreement with evidence suggesting the existence of an autocrine 
survival pathway in promyelin Schwann cells (Cheng et al., 1998; Dowsing et al., 
1999; Meier et al., 1999; Zorick et al., 1999). Recently, it has been suggested that 
Krox-20 is involved in altering the response of promyelinating Schwann cells to the 
Neuregulin and TGF-β pathways, which are involved respectively in proliferation 
and apoptosis in Schwann cells (Parkinson et al., 2001; Salzer et al., 1980).
Recent genetic studies demonstrated that Krox-20 expression is regulated by 
Oct-6 (Ghislain et al., 2002). This study has shown that Krox-20 expression is under 
the control of two different cis-acting regulatory elements, which independently 
act in immature and myelinating stages. These two elements are named as the ISE, 
active in immature Schwann cells and the MSE, active in myelinating Schwann 
cells. Both elements function in an axon-dependent manner. Interestingly, multiple 
potential Oct-6 binding sites are identified in the MSE, suggesting that Oct-6 directly 
regulates Krox-20 at the time of myelination. Subsequently, Krox-20 itself regulates 
multiple genes involved in myelin formation. Microarray expression analysis has 
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supported a role for Krox-20 in expression of genes like MPZ, PMP22, MBP, MAG, 
Cx32, and periaxin (Nagarajan et al., 2001). Krox-20 is also likely to be involved in 
regulating genes required for the synthesis of lipids and cholesterol.
Different Krox-20 mutations have been identified in patients with de- or 
dys-myelinating neuropathies, including congenital hypomyelinating neuropathy, 
Charcot-Marie-Tooth type 1 and Dejerine-Sottas syndrome. These diseases 
underscore the importance of Krox-20 in the myelination process. Until now, 
five dominant mutations have been identified in the zinc finger-binding domain 
of Krox-20 (Bellone et al., 1999; Timmerman et al., 1999; Warner et al., 1999). 
Nagarajan and colleagues (2002) have shown that the neuropathies associated 
with mutations in the DNA binding domain (DBD) of Krox-20 result in a dominant 
negative pathomechanism. The dominant negative inhibition of DBD mutations 
in Krox-20 can explain why Krox-20 heterozygous mice show no phenotype, while 
heterozygous Krox-20 DBD mutant patients are affected. In addition to dominant 
DBD domain mutations, a recessive mutation has been identified in the R1 
domain of Krox-20. This domain serves as an interaction interface for NGFI-A-
Binding Protein-1 (NAB1) and NAB2 proteins (Warner et al., 1999). These proteins 
negatively regulate the activity of Krox-20. It is suggested that in the absence of the 
inhibitory effect of NAB2, the higher amount of mutant protein in the nucleus leads 
to deregulation of target genes (Warner et al., 1999).
1.11. Scope of this thesis
In the introductory part of this thesis an overview of the current knowledge 
about Schwann cells and their development and the role of transcription 
factors during Schwann cell development has been provided. In part two of the 
introduction, several aspects of gene expression and cis-regulatory elements were 
discussed. In order to gain an understanding of the transcriptional regulatory 
networks that govern the development of the peripheral nerve tissue we analysed 
the cis-regulatory element within the Oct-6 locus that drive Schwann cell regulated 
expression. We demonstrated that this element is essential for Schwann cell 
regulated expression but does not contribute to other aspects of the Oct-6 expression 
pattern. The results of this study are described in chapter 2. Chapter 3 describes 
experiments in which we aimed to further define the functional domains within 
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the Schwann cell enhancer. The study described in chapter 4 identifies Brn-2 as an 
important Oct-6 redundant factor in Schwann cells. In addition, the results of the 
targeted deletion of Brn-2 and double Oct-6/Brn-2 knock out study are discussed in 
the same chapter. Finally, in chapter 5 the results obtained in the previous chapters 
are summarized and some future directions are discussed.
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Abstract
The Oct-6 Schwann cell enhancer (SCE) is both required and sufficient to 
direct regulated expression of the Oct-6 transcription factor gene during Schwann 
cell differentiation.  In this study we used a combination of functional reporter gene 
assays in transfected Schwann cells and transgenic mice and comparative genome 
analysis to identify regions within the 4.3 kb Schwann cell enhancer that are of 
functional importance. We identified two regions within the SCE that function as 
enhancers in transfected Schwann cells. These regions correspond to sequences 
that are highly conserved in the genomes of rat, human and dog and are named 
homology region 1 (HR1) and 2 (HR2). Although HR1, and to a lesser extent also 
HR2, functions as an enhancer in transfected Schwann cells, neither HR1 nor HR2 
has significant enhancer activity in Schwann cells of transgenic mice. However, the 
combination of HR1 and HR2 shows full activity, demonstrating that the Oct-6 SCE 
consists of at least two interdependent elements. These data suggest that multiple 
signalling pathways are integrated at the SCE to activate Oct-6 in Schwann cells at 
the appropriate time and level.
Introduction
Schwann cells, the main glia cells of the vertebrate peripheral nervous 
system (PNS), originate from the neural crest and differentiate in close association 
with axons through a number of developmental stages to give rise to the two 
morphologically distinct Schwann cell types that can be observed in the mature 
peripheral nerve. Myelinating Schwann cells generate and maintain a multi-lamellar 
insulating sheath around an associated axon while non-myelinating Schwann 
cells accommodate several smaller axons in cytoplasmic cuffs. The diversion of 
embryonic Schwann cells along a myelinating or non-myelinating differentiation 
route is primarily controlled by the axons with which the cells associate (Jessen 
and Mirsky, 2002).
Although the nature of the axonal signal(s) that promote myelination is 
unknown, two Schwann cell autonomous regulators of myelination have been 
identified and studied most extensively over the last decade. These are the POU-
domain transcription factor Oct-6/Tst-1/Scip/Pou3f1 (referred to as Oct-6 in this 
paper) and the zinc finger transcription factor Krox20 (Egr-2) (Topilko and Meijer, 
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2001). Both transcription factors are expressed dynamically in the Schwann cell 
lineage during development and nerve regeneration (Scherer et al., 1994; Zorick et 
al., 1996). Oct-6 expression is initiated in Schwann cell precursors and its regulated 
expression depends on continued axonal contact (Blanchard et al., 1996; Scherer 
et al., 1994). The highest levels of Oct-6 protein are observed at the promyelin 
stage of cell differentiation after which Oct-6 levels rapidly decline in actively 
myelinating Schwann cells (Arroyo et al., 1998). A role for Oct-6 in regulation 
of the myelination program is suggested by the analysis of the peripheral nerve 
phenotype observed in Oct-6 deficient and mutant mice (Bermingham et al., 1996; 
Jaegle et al., 1996; Jaegle and Meijer, 1998). In the absence of Oct-6, Schwann cells 
show a delay in the transition from the promyelin to the myelinating stage of cell 
differentiation. Similarly, Krox-20 deficient animals show a block at the promyelin 
stage of Schwann cell differentiation while mutations in the Krox-20 gene are 
associated with particular forms of hereditary motor and sensory neuropathies in 
man (Timmerman et al., 1999; Topilko et al., 1994; Warner et al., 1998). Genetic 
and cell biological studies have shown that Oct-6 and Krox-20 act in a genetic 
cascade (Topilko and Meijer, 2001). Oct-6 regulates the expression of a number of 
down-stream genes including Krox-20 (Blanchard et al., 1996; Ghislain et al., 2002). 
Consequently Krox-20 regulates an additional set of genes such as the major myelin 
genes and those involved in lipid metabolism (Nagarajan et al., 2001).
Since Oct-6 is the first transcription factor in this genetic hierarchy that is 
up-regulated in response to inter- and/or intra-cellular signals, it is important 
to understand how this gene is regulated. Previously, we identified a cis-acting 
regulatory element located 10 kilobases (kb) down-stream of the Oct-6 gene 
promoter and named it the Oct-6 Schwann cell enhancer or SCE. This 4.3 kb 
DNA element is characterized by the presence of two DNaseI hypersensitive 
sites (HSS) in chromatin of Oct-6 expressing cells (Mandemakers et al., 2000). We 
also demonstrated that the SCE is the decisive cis-regulating element governing 
Schwann cell-specific expression of the gene and that the SCE does not contribute 
to other aspects of the Oct-6 gene expression pattern (Ghazvini et al., 2002). To 
reveal the presence of putative cis-regulatory elements within the boundaries of 
the 4.3 kb SCE, we compared SCE orthologous sequences in the genomes of several 
mammalian species. This analysis revealed the presence of two highly conserved 
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regions, named HR1 and HR2, one of which (HR1) corresponds with one of the 
DNaseI HSS’s mapped in our earlier studies (Mandemakers et al., 2000). We first 
tested the relevance of these elements for SCE function in transfected primary 
Schwann cells and found that both conserved elements contribute to full enhancer 
activity. Subsequent analysis in transgenic mice revealed that neither HR1 nor HR2 
has significant enhancer activity. However, the combination of the two elements 
exhibits full SCE activity, suggesting that protein complexes assembled on both 
DNA elements act together to regulate expression from the linked promoter in 
Schwann cells.
Results
Phylogenetic analysis of the SCE
Comparative genomics is a powerful tool for identifying genes, functional 
domains and regulatory elements (Cooper and Sidow, 2003). Previously, we reported 
the identification of the human SCE and showed that this fragment, like its mouse 
orthologue, is sufficient to direct Schwann cell specific expression of a LacZ reporter 
gene in transgenic animals (Mandemakers et al., 2000). This result demonstrated 
that the regulatory elements for the Schwann cell specific expression of the Oct-
6 gene are conserved between human and mice. To further define this and other 
regulatory regions within the Oct-6 locus we compared the genomic sequence of 
the Oct-6 locus from mouse, human and rat using the Vista phylogenetic alignment 
tool (http://www-gsd.lbl.gov/vista) (Couronne et al., 2003; Shah et al., 2004). Figure 
1A illustrates the evolutionary conservation between the mouse Oct-6 locus and 
the human and rat Oct-6 locus as a percentage identity plot. Percentage identity 
is calculated for every nucleotide within a 100 bp wide window, 50bp upstream 
and 50bp down-stream of that nucleotide. The homology cut off is set at 50% for 
the human sequence and, because of the shorter evolutionary distance between 
mouse and rat, at 90% for the rat. The positions of previously mapped DNaseI 
hypersensitive sites are indicated above the graph (Mandemakers et al., 2000). As 
expected, high sequence conservation among the three mammalian species is found 
in the Oct-6 gene itself, including its long 3’UTR sequence. Additional regions of 
high sequence conservation are found up-stream and down-stream of the structural 
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gene. Some of these conserved sequences coincide with the previously mapped 
DNaseI hypersensitive sites (Figure 1).
 Within the limits of the previously defined Schwann cell enhancer element 
two conserved blocks of high sequence conservation are present (Figure 1B). We 
refer to these sequence blocks as Homology Region 1 (HR1) and Homology Region 
Figure 1
A. Genomic comparison of Oct-6 orthologous sequences in the genomes of mouse, human 
and rat using the VISTA alignment tool. Conservations levels greater than 50% are shown 
for the mouse versus human sequence comparison and 90% for the mouse rat comparison. 
The positions of the Oct-6 coding sequence, Oct-6 SCE, and DNaseI hypersensitive sites are 
indicated. The position of the different repeat elements such as SINE, LINE, and LTR are also 
shown above the plot. The homology above the 75% in mouse/human and above the 95% in 
mouse/rat has shown in colour. 
B. VISTA graph showing an enlargement of the conserved human and mouse Oct-6 SCE 
region. Two conserved blocks of high sequence conservation within the Oct-6 SCE are 
indicated and labelled homology 1 and 2 (HR1 & HR2). HR1 and HR2 both contain two 
separate highly conserved regions that are marked HR1a and HR1b, HR2a and HR2b.
2 (HR2). As shown in Figure 1B, DNaseI hypersensitive site 6 maps to HR1, while 
DNaseI HSS7 maps to non-conserved DNA sequences. The presence of HSS7 could 
be associated with the promoter region of a B2 repeat element.  
Deletion analysis of the SCE in transfected rat Schwann cells
To investigate which sequence elements within the SCE contribute to 
enhancer activity we generated a series of internal deletions and tested these for 
enhancer activity in transfected rat Schwann cells using a luciferase reporter assay. 
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Cultured primary rat Schwann cells express a number of genes that are normally 
expressed by non-myelinating Schwann cells in vivo. These genes include p75NTR 
(the low-affinity nerve growth factor receptor), brain derived neurotrophic factor 
(BDNF), and growth-associated protein 43 kDa (GAP-43) (Lemke and Chao, 1988). 
Elevation of intra-cellular cAMP levels results in up-regulation of myelination- 
associated genes such as Oct-6 and Krox-20 and down-regulation of genes associated 
with the non-myelinating phenotype (Figure 2A and (Arroyo et al., 1998; Monuki et 
al., 1989; Zorick et al., 1996). To test whether this in vitro differentiation paradigm 
could be used to dissect the Oct-6 SCE we first tested the responsiveness of the full 
enhancer. A luciferase reporter construct driven by the SV40 minimal promoter 
(pGL3 Promega) and the SCE cloned down-stream of the gene was transfected in 
rat Schwann cells in medium containing serum. Twenty-four hours later medium 
was removed and replaced by defined medium containing 20 µM Forskolin. 
Cells were harvested 24 hours later and tested for luciferase activity. As shown in 
Figure 2B, the SCE mediates an eight- to nine-fold activation of luciferase activity 
in response to the inductive signal, while a SV40 enhancer control is equally 
active in undifferentiated and differentiated cells. Activation of luciferase activity 
Figure 2 - A. Expression of Oct-6 in cultured rat Schwann cells, exposed to 20 mM Forskolin, 
is demonstrated in an electrophoretic mobility assay. Non-induced Schwann cells do not 
express Oct-6 (lane 1), while after induction of differentiation Oct-6 expression is detectable 
(lane 2). Addition of an Oct-6 polyclonal antibody results in the formation of a ternary 
complex with reduced electrophoretic mobility, confirming the presence of the Oct-6 protein 
in the complex (lane 3, SS=supershift). 2B. The Oct-6 SCE coupled to a luciferase reporter 
gene and a minimal SV40 promoter shows approximately ten times higher luciferase activity 
in differentiated Schwann cells versus non-differentiated Schwann cells. A generic enhancer, 
such as the SV40 enhancer is equally active in differentiated versus non-differentiated 
Schwann cells. Activation by the Oct-6 SCE of luciferase reporter gene expression depends 
on the presence of a minimal promoter, excluding the presence of a cryptic promoter within 
the Oct-6 SCE. 
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through the SCE is specific for Schwann cells, as the SCE does not mediate cAMP 
responsiveness in 3T3 cells (data not shown). 
Figure 3 - Schematic representation of the luciferase activity assay of Oct-6 SCE deletion 
constructs in Schwann cells. The position of the conserved HR1 and HR2 domains are 
highlighted. The position of DNaseI hypersensitive sites 6 and & 7 are indicated above the 
graph. Constructs 1 to 10 are overlapping deletions, generated in the context of the whole Oct-
6 SCE. Results are from one representative experiments performed in triplicate. Luciferase 
activity in cell extracts is normalized to β-galactosidase activity in the same cell extract. The 
values of luciferase activity are shown as a percentage of activity of the total SCE. The total 
experiment was performed at least three times and the results are reproducible.
We next tested the activity of the SCE deletion mutants in this differentiation 
paradigm (Figure 3).
Reporter gene activity of the various SCE deletion constructs is reported as 
a percentage of the full SCE activity. These results suggest that the major enhancer 
activity of the SCE is associated with sequences deleted in construct ∆3. Deletions 
in construct ∆10 result in a slight reduction of enhancer activity. The fact that ∆3 is 
located within the HR1, encouraged us to consider reduction in luciferase activity 
of deletion 10, since this deletion is also located within HR2. To determine whether 
the two regions HR1 and HR2 are relevant to SCE activity, we tested the luciferase 
activity of both regions in different combinations (Figure. 3). The combination of 
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both HR1 and HR2, as in construct ∆11, resulted in strong activation of reporter gene 
activity relative to the SCE. Also, HR1 alone (∆12) strongly activates transcription 
while HR2 only (∆13) marginally contributes to activity. These results suggest 
that indeed the major enhancer activity of the SCE is associated with HR1, in 
particular those sequences deleted in ∆3. We next tested whether these sequences 
(encompassing HR1a), deleted in ∆3, were sufficient to function as enhancer in 
Schwann cells. While HR1a sequences harbor considerable (D14 in Figure 3; 70% 
of full SCE activity) enhancer activity, its activity is further boosted when HR2a is 
included in the construct (D15 in Figure 3). Thus, HR1a and to a lesser extent HR2b 
function as enhancers in transfected Schwann cells and when combined, exhibit 
greater than additive activity. This analysis did not reveal a role for HSS7.
 
Deletion analysis in transgenic mice
In contrast to the data derived from the transfection studies described above, 
preliminary data from transgenic experiments did not reveal a role for HSS6/HR1 
or HR2 in SCE function (construct 2 and 3 in Figure 3B (Mandemakers et al., 
2000)). However, both these constructs terminated within HSS7, leaving open the 
possibility that HSS7 is required for HSS6/HR1 function in vivo. To resolve these 
issues we next examined the role of HSS6/HR1, HSS7 and HR2 in SCE function 
in vivo through the generation of transgenic mice carrying a LacZ reporter gene 
driven by the mouse heat shock protein 68 (hsp68) promoter (Rossant et al., 1991). 
LacZ reporter gene expression in neonatal Schwann cells was determined by whole 
mount X-Gal staining of founder transgenic mice. First we tested a construct that 
contains both HSS6 and HSS7. While around 80% of transgenic animals carrying a 
full SCE (construct 1 in Figure 4; 20 out of 26. This number is based on a summation 
of all transgenic animals generated with the full SCE) express the transgene in 
Schwann cells, only 1 out of 6 animals transgenic for construct 5 showed LacZ 
staining in the nerve, indicating that HSS6 and HSS7 are not sufficient to drive 
Schwann cell expression. Also, a construct containing HSS7 (construct 7) does not 
confer Schwann cell specific expression. Thus, both assays suggest that HSS7 does 
not play a role in activation of Oct-6 in Schwann cells. 
We next tested a set of constructs in which HR1, HR2 or both sequence 
elements are present. Neither HR1 nor HR2 alone is capable of directing Schwann 
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cell specific expression of the transgene (Figure 4 constructs 4 and 7 respectively). 
However, when both elements are combined 3 out of 4 founders expressed the 
Figure 4 - Functional 
dissection of the Oct-6 SCE 
in transgenic mice. The 
position of the conserved 
domains HR1 and HR2 are 
highlighted. The positions 
of the DNaseI hypersensitive 
sites 6 and & 7 are indicated 
above the graph. Transgenic 
founders were examined 
for expression of the lac-
Z reporter gene in sciatic 
nerve after 18 hours staining. 
In the columns next to the 
constructs, the number of 
the transgenics that express 
the reporter gene in Schwann cells are listed as #lacZ+ and the total number of the transgenic 
founders analysed as #tg.
reporter gene (Figure 4, construct 8) in Schwann cells, indicating that both elements 
are needed for full enhancer activity in vivo.
 
Phylogenetic comparison of SCE sequences from the mouse, human and dog 
genome (data not shown) reveals that HR1 and HR2 can be further subdivided in 
two regions (HR1a and b, HR2a and b respectively) of high sequence conservation 
(Figure 1A). As the luciferase assay suggests that the major enhancer activity of 
the SCE is associated with HR1a, we tested smaller versions of HR1 and HR2 in 
transgenic mice. First we tested HR1a alone. This element, like the entire HR1 
element, does not confer Schwann cell specific activation on the reporter gene 
(construct 3). However in combination with the HR2, 5 out of 5 transgenic animals 
now express the transgene in Schwann cells (construct 9). Next we tested the HR1a 
fragment in combination with the HR2b fragment and found that 3 out 5 transgenic 
founders express the transgene within the peripheral nerves (construct 10). Thus, 
the major enhancer activity within the boundaries of the SCE resides within 
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sequences covering HR1a and HR2b and these two elements are both required for 
Schwann cell specific activation of transcription.
Discussion
In the present study we have combined comparative genome analysis and 
functional analysis in cultured Schwann cells and transgenic mice, to identify and 
delineate two core elements that together make up the Schwann cell enhancer of 
the Oct-6 locus.
Comparative sequence analysis of mouse and human Oct-6 loci
Our initial comparative genome sequence analysis focused on approximately 
50kb surrounding the Oct-6 gene, a region for which HSS mapping data were 
available (Mandemakers et al., 2000; Mandemakers et al., 1999). This sequence 
analysis included human, mouse and rat sequences. In addition to the Oct-6 gene, 
including its promoter and long 3’ UTR, several strongly conserved sequences 
are found within the region analysed.  Two of the conserved regions correspond 
with the previously mapped HSSs 3 and 6. HSS6 is located within the Oct-6 SCE, 
approximately 10 kb down-stream of the Oct-6 CAP site (Mandemakers et al., 2000). 
HSS3 corresponds to a conserved sequence that is unique and that might be part of 
a transcription unit as one human est, derived from a pheochromacytoma, maps to 
this sequence. HSS3 is present in brain and ES cells, but not in liver or MES1 cells 
(Mandemakers et al., 2000). Additionaly, LacZ reporter constructs carrying DNA 
sequences encompassing HSS3 and HSS5 are expressed in the hair follicles of the 
skin (Mandemakers et al., 2000). It is therefore possible that HSS3 contributes to 
expression of Oct-6 in the skin. Further analysis of this element in transgenic mice 
should reveal the importance of this element for regulated expression of Oct-6 in 
these tissues. 
All other HSSs (2, 4, 5, 7 and 8) do not correspond to conserved sequences 
and most of them map to short repeat elements (SINE: see Figure 1). As many of 
these are actively transcribed by RNA polymerase III, it is likely that the DNaseI 
hypersensitivity is associated with transcriptional activity of these elements and not 
the Oct-6 gene (Deininger et al., 2003). Other conserved sequences could represent 
additional enhancer elements contributing to neuronal and skin expression of Oct-
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6. Alternatively, some of these sequences might be involved in interactions with the 
nuclear matrix as it has been shown that up to 10% of the conserved non-coding 
DNA sequences in the genome share characteristics of matrix attachment regions 
(MARs) (Glazko et al., 2003). Of specific interest is a conserved element located 
downstream of the SCE (grey arrowhead in Figure 1). This element shows 100% 
sequence conservation between mouse and human over a stretch of approximately 
250bp. This level of sequence conservation is even higher than that observed in the 
POU domain encoding region of the Oct-6 gene. Recently it was shown that this 
element is one of a family of approximately 500 DNA sequences, longer than 200bp, 
which are ultra-conserved in mammalian genomes (Bejerano et al., 2004). Some of 
these sequences are even conserved in the genomes of non-mammalian genomes. 
Also this ultra-conserved element in the Oct-6 locus is conserved in the genome of 
chicken and zebrafish (unpublished observations). Interestingly, the Brn-2 gene, 
which is expressed in Schwann cells in parallel with Oct-6, is also associated with 
an ultra-conserved sequence some 10 kb down-stream of the start codon of the Brn-
2 open reading fram. Indeed, these ultra-conserved DNA sequences are frequently 
found in close proximity or overlapping with genes encoding RNA and DNA 
binding proteins, particularly those involved in early embryonic development 
(Bejerano et al., 2004). The functional significance of these ultraconserved sequences 
is not known (Bejerano et al., 2004; Boffelli et al., 2004). 
Deletion analysis of SCE function
Deletion analysis in cultured Schwann cells revealed the presence of two 
regions within the SCE that exhibit enhancer activity. These regions correspond 
with sequences that are strongly conserved in mammalian genomes. Although 
both regions have enhancer activity in cultured Schwann cells, neither of the two 
have independent enhancer activity in vivo in transgenic mice. Instead, both the 526 
bp HR1a and 350 bp HR2b are required for activity in Schwann cells of transgenic 
mice. Why these elements behave different in the two assay systems is not clear. It 
is unlikely that these differences reflect the use of different minimal promoters (a 
minimal SV40 promoter in cultured Schwann cells versus a minimal hsp68 promoter 
in transgenic Schwann cells) or reporter genes in the different assay systems. Most 
likely these differences are caused by the difference in chromatin context (episomal 
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versus chromosomal) and cellular context (Schwann cells in a petri dish versus 
Schwann cells in a developing nerve). Such difference in behaviour of enhancers 
has been described for many enhancers and is generally attributed to the capacity 
of enhancers or locus control regions to influence chromatin structure or nuclear 
compartmentalization in a tissue–specific fashion (Dillon and Sabbattini, 2000). 
Conceptually, chromatin modulating activity and enhancer activity are functionally 
distinct mechanisms (Dillon and Sabbattini, 2000). Experimentally it is not possible 
to differentiate between these activities when reporter gene activity is the only 
experimental read out. It would therefore be of interest to investigate the histone 
acetylation status of the different transgene constructs and that of the DSCE allele 
in Schwann cells (Iizuka and Smith, 2003). At present, our data are compatible with 
the suggestion that enhancer function and chromatin modulating activity reside in 
two distinct elements. Alternatively, it is possible that HR1- and HR2-nucleoprotein 
complexes interact directly with complexes assembled at the promoter or through 
formation of a holo-complex. 
Enhancers are modular structures, which consists of arrays of transcription 
factor binding sites. Such arrays of high and low affinity binding sites are sufficient 
to integrate independent signals and convert them to a binary output: activation 
or repression of a linked gene promoter (Yuh et al., 1998). As discussed above, our 
data suggest that the SCE consist of at least two modules that are both required for 
activity in vivo. The signalling pathways that converge on these separate modules 
are not known yet. However, since Oct-6 mediates the initiation of myelin formation, 
signals that activate myelination in the PNS are likely candidates. It was shown 
by Lemke and colleagues that activation of PKA results in up-regulation of Oct-6 
levels in cultured Schwann cells (Monuki et al., 1989). We have tested our deletion 
constructs in Schwann cells in which PKA was activated by cAMP or forskolin. 
However, activation of reporter gene activity through the PKA pathway is probably 
indirect or requires additional Schwann cell specific factors, as the reporter cannot 
be activated by cAMP through the SCE in 3T3 cells, despite the presence of a CRE 
related sequence in HR1 (see supplementary information). Second, it has been 
suggested that the timing of myelination in the PNS results from counteracting 
neurotrophin signalling through the neurotrophin receptors p75NTR and TrkC 
(Chan et al., 2001; Cosgaya et al., 2002). This is of particular interest as it has been 
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shown that signalling through p75NTR results in activation of NF-κβ. Recently it was 
demonstrated that NF-κβ is involved in the Schwann cell differentiation and that 
inhibition of NF-κβ results in a failure to up-regulate Oct-6 (Nickols et al., 2003). 
Whether NF-κβ directly regulates Oct-6 remains to be determined. No clear NF-κβ 
binding sites are present within the minimal SCE (HR1a and HR2b). In addition, it 
has been shown that the extent, and maybe the timing, of myelin formation in the 
PNS depends on Neuregulin-1 signalling through the ErbB2/ErbB3 heterodimeric 
receptor (Garratt et al., 2000; Michailov et al., 2004). 
It is not known yet which transcription factors are the targets of these 
intracellular signals. Searching for potential transcription factor binding sites within 
the SCE using bio-informatics is of limited use as transcription factor DNA binding 
sites are notoriously degenerate. In addition, binding sites that are not represented 
in the database will be missed. Phylogenetic filtering for conserved binding sites has 
not been successful yet as the mammalian SCE sequences that have been analysed 
are too homologous. It is expected that inclusion of orthologous sequences from 
non-placental mammals such as opossum and rat kangaroo will greatly increase 
the power of this comparative analysis. Such comparison will prioritise potential 
binding sites for functional analysis in rat Schwann cells and transgenic mice. 
Materials and methods
Primary Schwann cell cultures
Cultures of Schwann cells were set up from postnatal day 1 to 4 rat sciatic 
nerves as described before (Brockes et al., 1979; Morrissey et al., 1991) with some 
modification. During dissection, nerves were collected in L-15 Leibovitz. Nerves 
were transferred to L-15 medium containing 0.1% collagenase (Boehringer), teased 
by dissections needles and incubated for 30 min at 37°C by regularly pipeting up 
and down in order do disrupt the nerves. Collagenase reactions were stopped by 
washing cells in L-15, 10% FCS twice. After washing, cells were plated on PRIMARIA 
tissue culture dishes (Becton Dickinson) in CB medium (Einheber et al., 1993), and 
incubated overnight at 37°C in presence of 5% CO2. The next day, medium was 
replaced by CB + 10µM ARA-C (Sigma). For expansion of cultures, cells were grown 
in proliferation medium, containing Dulbecco's modified Eagle's medium (Gibco), 
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3% FCS, 2µM Forskolin (Sigma) and 1% penicillin-streptomycin. Oct-6 induction is 
achieved by changing medium to Defined medium containing DMEM/F12 (Gibco), 
N2 supplement, antibiotics and + 100µM CTP-cAMP or 20µM Forskolin.
Transfection and luciferase assays
Cells were seeded in 6-well PRIMARIA plates (Becton Dickinson) and grown 
to 70-80% confluence. Rat Schwann cells were transfected with 1.125µg luciferase 
construct and 0.375µg pCMVβgal expression plasmid in the presence of fetal calf 
serum, using the FuGENE 6 transfection reagent (Roche). Cells were washed 18 
hours after transfection, and medium was changed to DF medium + 100µM CTP-
cAMP (Sigma). 72 Hours after transfection, cells were washed with PBS and lysed 
in Reporter lysis buffer (Promega). β-Galactosidase (β-gal) levels were measured 
in an activity assay using 2-nitro-phenyl-galacto-pyranoside (ONPG) substrate. 
Luciferase was assayed on a luminometer (TOPCount NXTv2.13, Packard) using 
the Steady GLO luciferase assay substrate from Promega. All the experiments were 
performed at least three times each in triplets. 
Cloning (Plasmid constructs)
Mouse SCE sequence (4.5 kb) was amplified from a genomic subclone 
(129sv DNA), using primers 5’SAL SCE: ATCGCGTCGACCTTCAGGTCTCCGT
GAGTAG and 3’BglII SCE: GAAGATCTGGATAAAGCCTAAAGGTTGGCCAT
GAC and cloned into SalI-BglII site of pSP72 plasmid (Promega). Deletions 1 to 
8 were generated by amplification of SCE-pSP72 using two primers in opposite 
directions:
Deletion construct Primers
SCE D1 SCE1for primer (CGGAATTCGTCAAGTTCTGGGCTAAATGTAAGG)3’BglII SCE (GAAGATCTGGATAAAGCCTAAAGGTTGGCCATGAC)
SCE D2 SCE1as primer (CGGAATTCAGGCTGTATCAACTATAGCTTCTTTGG)SCE2for primer (CGGAATTCCAGAATCTGGGCACAGCTGG)
SCE D3 SCE2as primer (CGGAATTCTCGAGCTGAGTCCTCAGGGCC)SCE3for primer (CGGAATTCAGGCAACCTCCAACCTACC)
SCE D4 SCE3as primer (CGGAATTCGGTCTGGCCCATCAGCCTACC)SCE4for primer (CGGAATTCCATGAAGTAGCACCAACCCTCC)
SCE D5 SCE4as primer (CGGAATTCAAGTTGAATATGCAGGACAGTGGC)SCE5for primer (CGGAATTCTGGCACCCCATTCTGTCTAATC)
SCE D6 SCE5as primer (GCGAATTCGGGAGGTTTCCAGGAGCTTGCC)SCE6for primer (CGGAATTCGGCATATGTGTTGAAGTGCATG)
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SCE D7 SCE6as primer (CGGAATTCGAAACAGGTTTCTCTTTCTTTCCCCTC)SCE7for primer (CGGAATTCTGTCTGAAGACAGCTACAGTGTACTTAC)
SCE D8 SCE7as primer (CGGAATTCCCATTACAGATGGTTGTGAGCC)SCE8for primer (CGGAATTCAAGGTAGTGGGAGGGCAGAG)
SCE D9 SCE8as primer (CGGAATTCGTATTCGTGTGTGTCCGGCTGAC)SCE9for primer (CGGAATTCAAGAAGTGGTGAGGAGGGCC)
SCE D10 5’SAL SCE (ATCGCGTCGACCTTCAGGTCTCCGTGAGTAG)SCE9 as primer (CGGAATTCATCATGCTTGAAGGACTCCCCAG)
Amplified PCR products were digested with EcoRI and ligated back. Next, 
deletion fragments were isolated as a Sal I-Bgl II and cloned into Sal I-Bam HI 
sites of pGL3-promoter vector. SCE D11 is generated by cloning products of Sal I 
primer 10 (TGTCGACTTGAGGATGTCGCCTGCCCTCTAG) and EcoRI primer 11 
(AGAATTCCCAGTCCTTAGCAATGAAGC) as Sal I-EcoRI fragment and SCE8for 
and SCE3’BglII primers as a EcoR I-Bgl II fragment into Sal I-Bam HI site of pGL3-
promoter luciferase vector. D14SCE (HR1a) is generated by cloning product of 
SCE12for and SCE 12as primers as a Sal I-EcoRI into pSP72 vector. D15SCE (HR1a 
and HR2b) by cloning the Sal I- EcoRI fragment of HR1a (product of SCE12for and 
SCE12as primers) and EcoRI-Bgl II fragment of HR2b (generated by cloning the 
PCR product of primer SCE9for and 3’BglII SCE into EcoRI- Bgl II) into pGL3p 
vector. 
Transgenic mice
The generated deletion constructs were cloned into Hsp68-LacZ vector 
referred as p610ZA by (Mandemakers et al., 2000) with some adaptations. DNA 
fragments were excised from each deletion construct using appropriate restriction 
enzymes and isolated from agarose gel. The isolated DNA was purified using 
elutip-D-mini columns (Schleicher and Schull). The DNA was dissolved in injection 
buffer (10mM Tris-HCl pH 7.5, 0.08mM EDTA pH 8.0) and injected into fertilised 
eggs derived from a FVB/N x FVB/N mating as described (Hogan, et al., 1994). 
Pups born at postnatal day 1 were tested for the Lac-Z expression by whole mount 
β-galactosidase staining and analysed for genotype by Southern blotting.
 
Whole mount β-galactosidase staining
Postnatal day 1 mice were sacrificed by decapitation followed by fixation in 
lac-Z fixative (1% Formaldehyde, 0.2% Gluteraldehyde, 2mM MgCl2, 5mM EGTA, 
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0.02% NP40 in PBS) for 1 hour at room temperature (RT). Tissues were washed in 
PBS/0.02% NP40 for 3 times at RT. β-Galactosidase staining done overnight at RT 
in staining solution (5mM K3Fe(CN)6, 5mM K4Fe(CN)6.3H2O, 2mM MgCl2, 0.01% 
Nadeoxycholate, 0.02% NP40 and 1mg/ml X-gal). The staining was stopped by 
extensively washing in PBS/0.02% NP40 and post-fixed in a 4% formaldehyde/PBS 
fix. 
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Conclusions and future prospects
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Although it is generally accepted that the fate decision in immature 
Schwann cells to adopt a myelinating or a non-myelinating phenotype results 
from interactions with axons, the molecular identity of these interactions and the 
subsequent down-stream events within the Schwann cells are still largely unknown. 
In the last decade, a substantial body of information has been gathered about the 
intracellular signaling pathways and transcription factors underlying myelination. 
Given the complexity of the myelination process, which involves dramatic changes 
in cell morphology and metabolism, it seems reasonable to expect that multiple 
signaling pathways are involved in this process.
Signalling pathways will converge on transcription factors involved in the 
gene expression program of myelination. Prime targets are the transcription factors 
Oct-6 and Krox20. Genetic and cell biological studies have shown that Oct-6 is the 
first of these two transcription factors to be strongly activated in promyelinating 
cells. This results in the activation of Krox20 and up-regulation of myelin gene 
expression (Topilko and Meijer, 2001).
In this thesis, we focus on the role of the Schwann cell specific enhancer 
(SCE) in regulating Oct-6 gene expression during differentiation of Schwann cells. 
Previous studies in our group have shown that Oct-6 SCE is sufficient for correct 
temporal expression of the Oct-6 gene in Schwann cells of the developing and 
regenerating peripheral nerve tissue. One important question, addressed in this 
thesis, was whether the Oct-6 SCE is also required for Oct-6 expression in Schwann 
cells. This question is answered in chapter 2 through the generation and analysis of 
mice in which the SCE is homozygously deleted. We showed that the Oct-6 SCE is 
the decisive cis-regulatory element governing Schwann cell specific expression. In 
addition, we demonstrated that the SCE does not contribute to other aspects of the 
Oct-6 gene expression pattern. 
The peripheral nerve phenotype of Oct-6DSCE/DSCE mice is very similar to Oct-
6βgeo/βgeo mice, strongly indicating that the phenotype of Oct-6 null mice is Schwann 
cell autonomous. As the DSCE allele is a Schwann cell specific hypomorphic Oct-
6 allele and the peripheral nerve phenotype in Oct-6DSCE/DSCE mice is slightly less 
severe than in Oct-6 null mice, it is possible that the low residual amounts of Oct-6 
present in the DSCE homozygous Schwann cells results in a moderately increased 
rate of Schwann cell differentiation relative to Oct-6 null Schwann cells. Therefore, 
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we suggested that the level of Oct-6 is important for Schwann cell differentiation. 
This conclusion is supported by results from another study by Weinstein and 
colleagues. Transgenic mice expressing a truncated Oct-6 protein (DSCIP) under 
control of the P-zero promoter in Schwann cells (Weinstein et al., 1995) show 
premature myelination and hypermyelination. The use of the P-zero promoter 
results in premature high-level expression of DSCIP protein in immature Schwann 
cells. The premature myelination, hypermyelination and frequent polyaxonal 
myelination all suggest that DSCIP functions as a dominant positive form of Oct-6 
(Wu et al., 2001). Taken together, these results indicate that Oct-6 acts in a dosage-
dependent manner.
In chapter 3, we focused on the structure of the Oct-6 SCE. Through pairwise 
sequence comparison of SCE orthologous sequences in the genomes of human, 
mouse, dog and rat, we identified two highly conserved regions within the 
boundaries of Oct-6 SCE. Using a Schwann cell transfection assay we demonstrated 
that homology region 1 (HR1) acts as a strong enhancer while homology region 2 
(HR2) exhibits a weak enhancer activity in vitro. We also demonstrated that the 
major enhancer activities are contained within the HR1a and HR2b sub-regions. 
In contrast, neither HR1a nor HR2b exhibit any Schwann cell specific enhancer 
activity in transgenic animals. However, the combination of the two elements 
shows full SCE activity.
At present, we do not know what transcription factors bind to these elements 
and how they interact to form a functional enhancer. However, preliminary DNaseI 
footprinting experiments, using protein extracts of differentiated Schwann cells, 
indicated the presence of several putative binding sites for transcription factors 
within the HR1a sequence. The combined approach of DNAse I footprinting 
and using bioinformatics should produce candidate transcription factors whose 
relevance should study in details. 
We suggest that Oct-6 SCE consists of at least two separate modules that 
might independently or interdependently bind to PIC (Fig. 1). Most likely, each 
module includes multiple binding sites to recruit specific regulatory nucleoprotein 
complexes and architectural proteins, like in many other eukaryotic enhancers 
(Carey, 1998). What are the contributions of HR1a and HR2b to full enhancer 
activity? The current view for transcription of any gene is that diverse regulatory 
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cues integrate at the promoter to adjust the level of RNA transcription (Goodrich 
et al., 1996). It might be expected that different signaling pathways involved in the 
initiation of the myelination program, converge on these separate modules and 
activate Oct-6 gene expression, which in turn regulates the onset of myelination. In 
recent years, several signaling molecules and their receptors have been implicated 
in myelination of the PNS, including the neuregulin, adenosine triphosphate, 
steroid hormones, and the neurotrophins BDNF and NT3.
Several lines of evidence suggest that neurotrophins, in particular BDNF and 
NT3, have important roles not only during Schwann cell development (cell survival 
and growth) but also in myelination (Meier et al., 1999). It is known that BDNF 
and NT3 can bind to different receptors from the tropomyosine-related kinase 
(Trk) family of tyrosine kinase receptors (Roux and Barker, 2002) and p75, the low 
affinity neurotrophin receptor (p75NTR), a member of the TNF receptor superfamily 
(Baker and Reddy, 1998). It is assumed that during Schwann cell proliferation, NT3 
activation of TrkC inhibits myelination and at the same time enhances Schwann 
cell migration. TrkC induces the migration of the Schwann cells through the Rac1/
Cdc42/c-jun N-terminal kinase signaling pathway (Yamauchi et al., 2003). At the 
onset of myelination, NT3 expression is down-regulated, while BDNF continues to 
be expressed during myelination (Cosgaya et al., 2002). It has been demonstrated 
that activation of p75NTR by BDNF, prior to myelination, has two striking effect on 
promyelinating Schwann cell. First, the interaction of BDNF and p75NTR stimulates 
the Scr kinase-dependent activation of guanine-nucleotide exchange factors Vav2 
and RhoA, leading to inhibition of Schwann cell migration (Yamauchi et al., 2004). 
Second, this binding enhances myelination (Cosgaya et al., 2002). Schwann cells 
express p75NTR during development up to myelination, but this receptor is rapidly 
down-regulated at the onset of myelination. Therefore, it is proposed that p75NTR 
is required for the initiation of myelination but not myelination itself (Hempstead 
and Salzer, 2002). It is likely that p75NTR also plays a role in re-myelination following 
nerve injury, as it is rapidly up-regulated in reactive Schwann cells (Hempstead 
and Salzer, 2002). The signaling events associated with myelination down-stream 
of p75NTR are poorly understood. It is likely that p75NTR interacts with down-stream 
signaling elements through interaction with TNFR-associated factors (TRAFs). It 
has been demonstrated that some TRAFs link the TNF receptors to NF-κB signaling 
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(Bradley and Pober, 2001). Therefore, NF-κB is an attractive candidate regulator 
of Schwann cell myelination. Indeed, compelling evidence has been provided 
to suggest that NF-κB is involved in Schwann cell differentiation and possibly 
myelination (Nickols et al., 2003). Inhibition of NF-κB in neuron-Schwann cell co-
cultures or DRG explants of p65-/- mice, show a significant decrease in myelination 
and an arrest of Schwann cell differentiation at the promyelin stage. However, it 
remains unclear what the exact role of NF-κB is in myelin formation. Nickols and 
colleagues (2003) also demonstrate that in the absence of NF-κB, Oct-6 is not up 
regulated in promyelinating Schwann cells. It is therefore possible that Oct-6 is a 
direct target of NF-κB. If so, one would expect to find NF-κB binding sites within 
the Oct-6 SCE, in particular within the regions defined in this thesis, namely HR1a 
and HR2b. However, we could not find any potential NF-κB binding site within 
HR1a and HR2b, using the Mathinspector or Transfac algorithms. Furthermore, 
a constitutively active form of NF-κB does not activate a SCE reporter construct 
(unpublished observations). Therefore the link between NF-κB and Oct-6 in 
regulating myelination remains unclear.
Neuregulin-1 (Nrg-1) is not only involved in early survival of Schwann 
cell precursors but also provides, at later stages of development, a signal for the 
regulation of myelin sheath thickness (Michailov et al., 2004). It has been known for 
a long time that myelin sheath thickness (the number of myelin wraps) and axonal 
diameter correlate positively (Friede and Samorajski, 1967). Indeed, axonal cues 
determine the number of myelin wraps produced by oligodendrocytes or Schwann 
cells (Fanarraga et al., 1998). Using a transgenic approach, it was demonstrated that 
the amount of axonal Nrg-1 type III determines the number of wraps of Schwann 
cells around the axon (Michailov et al., 2004). Neuronal overexpression of Nrg-
1 causes hypermyelination of axons in vivo in transgenic animals. Furthermore, 
absence of ErbB2 expression in homozygous ErbB2 animals results in reduced 
numbers of myelin wraps. Thus, neuregulin-1 signaling is involved in the number 
of myelin wraps produced. It is not clear whether neuregulin-1 is also involved in 
the initiation of myelination. Previously, it has been shown that neuregulin-1 type III 
is required for survival of Schwann cell precursors during embryonic development 
(Garratt et al., 2000a; Garratt et al., 2000b; Lemke, 1996). In contrast, neuregulin 
induces demyelination and dedifferentiation of Schwann cells in myelinating 
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sensory neuron-Schwann cell co-cultures (Zanazzi et al., 2001). It appears that 
the effect of neuregulin-1 is strongly context dependent. One explanation of this 
phenomenon has been provided by Colognato and colleagues who suggest that 
the effect of Nrg-1 is modified by integrin signaling (Colognato et al., 2002). Their 
model suggests that interaction of Nrg-1/ErbB2 and integrins leads to activation of 
MAPK signaling for the Schwann cell survival, while interaction of Nrg-1 and ErbB 
receptors activate the phophatidyl-inositol-3-phosphate (PI3) kinase and induce 
differentiation. 
A third signal potentially involved in regulating the onset of myelination 
in the PNS is provided by electric activity of the axon. (Stevens et al., 1998). Some 
studies have shown that the low frequency impulse (0.1 Hz) activity of axons 
inhibits myelination, while higher impulse activity (1 Hz) has no effect (Stevens et 
al., 1998). In vitro studies showed that lower stimulation activity of axons decreases 
expression of the cell adhesion molecule L1-CAM. Previously, it was suggested 
that L1-CAM has a critical role in initiation of myelination (Seilheimer et al., 1989a; 
Seilheimer et al., 1989b; Wood et al., 1990). It is also suggested that during Schwann 
cell development, impulse activity might play a role in the onset of myelination, 
and that this effect is mediated through adenosine triphosphate (ATP) (Stevens 
and Fields, 2000). ATP activates the purinergic receptors expressed on the cell 
membrane of Schwann cells. As a result, Ca2+ is released from its intracellular 
stores, activating Ca2+/calmodulin kinase and MAP kinase. It is believed that these 
signals postpone the differentiation of Schwann cells until they become exposed to 
appropriate axon-derived signals (Stevens and Fields, 2000).
Another signaling pathway important for axonal ensheathment and 
myelination is laminin-2 and its receptor β1 integrin. It has been shown that 
β1 integrin in immature Schwann cells is important for ensheathing axons in a 
1:1 manner and to progress to promyelinating stage. Disruption of β1 integrin 
specifically in Schwann cells leads to inhibition of radial sorting in immature 
Schwann cells (Feltri et al., 2002). 
Taken together, the components of one or more pathways mentioned 
above can potentially be involved in regulation of Oct-6 through the Oct-6 SCE. 
Identification of the nuclear factors that bind to HR1a and HR2b will be instrumental 
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in unraveling the regulatory network up-stream of the Oct-6 transcription factor 
leading to onset of myelination.
To realize this aim it will be necessary to further narrow down the critical 
regions within the SCE by generating further deletions in the context of the HR1a 
and HR2b in a luciferase reporter construct. The fragments with significant enhancer 
activity might then be used in a DNA pull-down assay using biotin tagged dsDNA 
oligonucleotides and identification of bound proteins by mass spectrometry. 
In a parallel approach, biochemical experiments such as DNaseI footprinting 
are required to find out what the potential protein binding sequences are and which 
putative factors bind to these sequences. The role of these potential binding sites 
could be investigated by mutagenesis. Cultured rat Schwann cells allow us to test 
the functionality of these mutated sites in the context of HR1a and HR2b, coupled 
to a luciferase reporter gene. Subsequently, constructs with a critical binding 
sequence can be verified in vivo by mutagenesis or deletion through homologous 
recombination in mice. Moreover, these sequences might be used to identify the 
factors that bind to them by screening of a Schwann cell cDNA library in a yeast 
one-hybrid system.
In another approach, similar to the one described in the previous paragraph, 
one could generate a double strand oligonucleotide chip, on which overlapping 
fragments of the Oct-6 SCE sequence are spotted and determine which DNA 
fragments are bound by nuclear factors derived from P1 nerves or cultured Schwann 
cells. In principle, this approach would allow identification of all the proteins 
expressed in the Schwann cells nucleus, including activators and repressors, and 
thus potentially involved in the regulation of the Schwann cell specific expression 
of the Oct-6 gene. 
Further investigation of transcription factors up-regulated in Schwann cells 
between E18 and the day of birth, using a luciferase reporter assay might lead to 
identification of specific factors binding to HR1a and HR2b elements.
Another interesting question is how HR1a and HR2b elements activate 
transcription from the Oct-6 promoter. Using a transgenic mouse approach, 
described in chapter 3, we demonstrated that both HR1a and HR2b are required 
for enhancer activity in transgenic mice. It appears that the distance between these 
two elements has no dramatic effect on enhancer function, since in our transgenic 
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Figure 1- Schematic presentation of different mechanisms for activation of Oct-6 gene 
expression through HR1a and HR2b. 
5.1 Identifying Oct-6 redundant factor
In chapter 4, we demonstrated that the class III POU domain protein Brn-2 
functionally overlaps with Oct-6 during Schwann cell development. This conclusion 
is derived from two different genetic experiments. First, we showed that over-
expression of Brn-2, under control of the Oct-6 SCE, in Oct-6 deficient Schwann 
cells resulted in an increase of the number of myelinated Schwann cells, partially 
rescuing the Oct-6 mutant phenotype. Second, Schwann cell-specific deletion of 
Brn-2 in an Oct-6 deficient background resulted in an increase in severity of the 
delayed hypomyelinating phenotype. Although we concluded that Brn-2 shares a 
role with Oct-6 during Schwann cell development, we observed that a quantitatively 
higher amount of Brn-2 protein is required to initiate myelination on schedule. This 
difference in biological function of Brn-2 and Oct-6 could arise from differences 
in affinity for transcriptional cofactors or other transcription factors as discussed 
constructs these two elements are joind. At present we suggest that nucleoprotein 
complexes binding to HR1a and HR2b might either interact independently 
with components of the preinitiation complex (PIC) at the promoter (Fig 1A) or 
interdependently, through formation of a holocomplex (Fig. 1B). 
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in chapter 4. In particular it has been suggested that a specific POU/Sox protein 
combinatorial code exists (Kuhlbrodt et al., 1998). Since the cooperative activation 
of a synthetic reporter construct by Oct-6 and Sox10 requires the N-terminal domain 
of both proteins, it will be of interest to investigate whether swapping the amino-
terminal portions of Oct-6 and Brn-2 is sufficient to confer Sox10 cooperativity on 
Brn-2. This is of particular interest as Sox10 is strongly expressed in the Schwann 
cell lineage. Transgenic constructs in which the amino-terminal portions of the 
Oct-6 and Brn-2 protein are swapped have been generated in our group and are 
currently crossed into the Oct-6DSCE/DSCE background to study their ability to rescue 
the delayed myelination phenotype.
Another possible explanation for the difference in biological function 
between Oct-6 and Brn-2 is that Brn-2 function is modified or inhibited through 
interaction with another protein that does not interact with Oct-6. Such a protein 
has been described for Brn-2. This protein, which is called “poly-glutamine tract 
binding protein” or PQBP-1, was shown to interact with Brn-2 through its amino-
terminal glutamine stretch of 23 residues. This interaction inhibits Brn-2’s ability to 
activate an octamer containing reporter construct (Waragai et al., 1999). It is thus 
suggested that binding of PQBP-1 to polyglutamine tracts of regulatory proteins, 
including Brn-2, modulate transcription of target genes during differentiation. It 
will be of interest to investigate the role of PQBP-1 and its interaction with Brn-2 
during Schwann cell differentiation. Study of the expression level of PQBP-1 by 
semi-quantitative RT-PCR has shown that indeed PQBP-1 is expressed in Schwann 
cells. However, no difference in the level of expression of the PQBP-1 gene in Oct-6 
deficient Schwann cells is observed (M. Jaegle, unpublished data). If PQBP-1 does 
play a role in modulating Brn-2 activity it is anticipated that overexpression of 
PQBP-1in Schwann cells will result in a more severe Oct-6 mutant phenotype. Since 
both Oct-6 and Brn-2 are similarly expressed during Schwann cell development, 
it is possible that both of these genes are regulated through the same signaling 
pathways. The Schwann cell specific regulatory sequences in the Brn-2 locus are 
unknown. There is no obvious sequence homology between Oct-6 and Brn-2 
outside the POU domain. Potential regulatory sequences could first be identified 
through phylogenetic sequence comparison and subsequently tested for activity in 
transgenic mice or in cultured rat Schwann cells. 
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5.2 Schwann cell specific regulatory elements
To date, several Schwann cell specific cis-regulatory elements has been 
identified including the Oct-6 SCE, the subject of this thesis, Krox-20 SCEmse (Krox-
20 myelinating Schwann cell element) (Ghislain et al., 2002), MbpSCE1 (Forghani 
et al., 2001; Taveggia et al., in press), and a 10 kb region of the PMP22 (Maier et al., 
2002). 
Work described in this thesis demonstrated that the Oct-6 SCE is required for 
Oct-6 gene expression in Schwann cells during myelination and regeneration. One 
potential target of Oct-6 regulation is Krox20. Recently, Ghislain and colleagues 
have identified the cis-acting sequences that regulate Krox-20 expression during 
myelination and regeneration in an axon dependent manner (Ghislain et al., 
2002). Interestingly, they identified multiple candidate Oct-6 binding sites within 
the Krox-20 MSE by biochemical studies. These results indicate that Oct-6 might 
directly regulate transcription of Krox-20 (Ghislain et al., 2002). However, in chapter 
2 we showed that Krox-20 expression is activated through an Oct-6 independent 
mechanism in Schwann cells of Oct-6DSCE/DSCE mice, albeit with a delay. Although 
there is no evidence that the delayed activation of Krox-20 is mediated through this 
element, it is possible that another POU factor, related to Oct-6, can occupy Oct-6 
binding sites in the Krox-20 enhancer and activate the Krox-20 gene. Previously, 
it was suggested that Brn-5, a class VI POU domain protein, might be a potential 
candidate as Oct-6 redundant factor (Wu et al., 2001). However, we demonstrated 
that overexpression of Brn-5, under control of the Oct-6 SCE, in Oct-6 deficient 
Schwann cells is not able to rescue the differentiation delay. 
A recent publication about the mouse claw paw (clp) mutation indicates the 
existence of multiple parallel pathways for initiation of myelination in Schwann 
cells (Darbas et al., 2004). Similar to Oct-6 null mice, mice homozygous for the clp 
allele show a delay in initiation of myelination in the peripheral nerves. Although 
clp/clp Schwann cells express Oct-6 at high level, the expression of Krox-20 is 
delayed. 
Krox-20 plays an important role in the up-regulation of myelin genes 
including P-zero, MBP and PMP22 (Nagarajan et al., 2001; Topilko et al., 1994). 
Schwann cells of Krox-20-/- animals show a strong reduction of P-zero, MBP, and 
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Figure 2- Model of regulatory cascade of myelination.
In summary, intracellular pathways involved in myelination converge on 
HR1a and HR2b elements located within the Oct-6 SCE and activate expression 
of Oct-6. Subsequently, Oct-6 regulates the expression of its down-stream target 
genes including Krox-20. Oct-6 probably acts on the Krox-20 MSE and up-regulates 
Krox-20 expression. Krox-20 can also be activated through an Oct-6 independent 
mechanism as in clp Schwann cells. Although Oct-6 appears to be required for 
Krox-20 activation, it is not sufficient for the activation of Krox-20 and myelination 
as it seen in clp animals. Krox-20 is involved in the regulation of a set of genes 
involved in myelination, including myelin genes P-zero, MBP, and PMP22. The 
Oct-6 redundant factor Brn-2 is a positive regulator of myelination. Brn-2 and Oct-6 
expression are regulated independently.
PMP-22 expression. In Oct-6 SCE deficient Schwann cells, P0 level is upregulated 
after activation of Krox-20 (Ghazvini et al., 2002). In addition, in vitro studies have 
shown that Krox-20 transactivates the P0 promoter (Zorick et al., 1999). Surprisingly, 
mutation analysis demonstrated that none of the potential Krox-20 binding sites in 
the MbpSCE1 are necessary for activation of a Lac-Z reporter gene in the peripheral 
nerves of transgenic animals (Taveggia et al., in press; However, these experiments 
do not rule out a role for Krox-20 acting through non-consensus DNA binding 
sites. Another possibility is that additional regulatory elements, containing Krox-20 
binding sites, are involved in activation of the Mbp gene, as Forghani and colleagues 
have suggested (2001).
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Summary
The reciprocal interactions between Schwann cells and their associated 
axons are important during development, maintenance, and regeneration of the 
peripheral nervous system. Schwann cells arise from the neural crest cell and 
develop through different transitional stages to non-myelinating and myelinating 
Schwann cells found in the mature peripheral nerves. In recent years, evidence has 
accumulated to suggest that in particular two transcription factors play pivotal roles 
in regulation of the myelination program. These transcription factors are Oct-6, 
and Krox-20. Genetic studies have shown that the POU domain transcription factor 
Oct-6 is a major regulator of Schwann cells assuring the timely progression of cell 
differentiation from the promyelinating to myelinating stage. Additionally, it was 
shown that expression of Oct-6 in Schwann cells is under control of axonal signals, 
which ultimately converge on the Oct-6 Schwann cell specific regulatory element 
(Oct-6 SCE). The Oct-6 SCE is sufficient to drive the correct expression of the Oct-6 
gene or a reporter gene, during development or regeneration. Consequently, Oct-6 
regulates a set of down-stream genes, including the zinc-finger protein Krox-20. 
Homozygous deletion of Oct-6 or Krox-20 in mice leads to arrest of Schwann cells 
at the promyelin stage. While the differentiation block of Oct-6 deficient Schwann 
cells is transient, this block is permanent in Krox-20-/- Schwann cells. 
In this thesis, we demonstrated that the Oct-6 SCE is not only sufficient, but 
also required for correct spatial and temporal expression of Oct-6 in the Schwann 
cell lineage. Moreover, our results demonstrate that Oct-6 acts in a dose dependent 
mechanism and that Oct-6 function is required in the Schwann compartment of the 
developing nerve. 
Our structural analysis of the SCE identified two regions that together function 
as an enhancer of the Oct-6 gene in vitro and in vivo. In our transgenic studies we 
showed that both these elements are required for full enhancer activity. Therefore, 
we suggested that Oct-6 SCE enhancer activity depends on the interdependent 
interaction of these elements with the basal transcription factors assembled at the 
promoter.
Further, we identified Brn-2, a POU domain transcription factor closely 
related to Oct-6, as an Oct-6 redundant factor in Schwann cell development. We 
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showed that Brn-2 expresses in Schwann cells in a similar developmental profile as 
Oct-6. While overexpression of Brn-2, under control of the Oct-6 SCE, can partially 
rescue the developmental delay of Oct-6 deficient Schwann cells, ablation of Brn-2 
and Oct-6 in Schwann cells results in a more severe phenotype.
The studies presented in this thesis, deepen our insight in the molecular 
mechanisms of myelination and the role Oct-6 plays in this important and 
fascinating cellular differentiation process. It is hoped that this deepening of our 
understanding of the molecular processes that underlie nerve development and 
homeostasis will one day result in the development of rational strategies to combat 
the many debilitating diseases of the peripheral and central nervous system. 
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Nederlandse samenvatting
Meercellige organismen ontwikkelen zich uit één enkele cel, namelijk 
de bevruchte eicel. De eicel vermenigvuldigt zich gedurende de embryonale 
ontwikkeling. Celdeling leidt tot het ontstaan van een groot aantal cellen die 
vervolgens verschillende karakteristieke functies aannemen in een proces dat 
celdifferentiatie heet. Celdifferentiatie zorgt voor het ontstaan van een grote variatie 
van cellen, zoals bloedcellen, spiercellen, zenuwcellen, huidcellen, levercellen enz. 
De genetische informatie die nodig is voor het bouwplan en het functioneren 
van de cellen is opgeslagen in het DNA in de vorm van genen (het genoom). 
Elke cel bevat hetzelfde DNA, maar door activiteit van een bepaalde set genen 
en onderdrukken van andere genen, ontstaan verschillen in de functie van cellen. 
Activiteit van een gen houdt in dat door een heel gereguleerd proces, een gen 
kan worden afgelezen (komt tot expressie). Hierbij ontstaat een RNA molecuul 
(transcriptie) dat vervolgens omgezet wordt in een eiwit (translatie). Eiwitten zijn 
de functionele onderdelen van de cel. Het is van belang dat elke cel de juiste set van 
genen op het juist moment vertaalt naar eiwitten. Dit wordt verzorgd door (eigen) 
controle-mechanismen in elk celtype. Een deel van de celcontrole-mechanismen 
wordt uitgevoerd door transcriptie factoren. Transcriptie factoren zijn speciale 
eiwitten die specifiek op bepaalde plaatsen aan het DNA kunnen binden en zorgen 
dat een gen afgelezen kan worden of juist niet. 
Het onderzoek dat in dit proefschrift wordt beschreven, is gericht op de rol 
van een transcriptie factor genaamd Oct-6. Het Oct-6 gen komt tot expressie in 
verschillende cel types zoals bepaalde zenuwcellen in de hersenen, haar follikels 
en in Schwann cellen. Schwann cellen groeien naast de zenuwbanen (axonen) in 
het perifere zenuwstelsel en vormen een isolerende vetlaag rond de axonen. Deze 
vetlaag heet de myeline schede. De aanwezigheid van deze myeline schede is 
belangrijk voor het sneller geleiden van zenuw signalen in de vorm van elektrische 
impulsen. De aanmaak van de myeline schede is afhankelijk van contact met axonen. 
Echter, niet alle axonen in het perifere zenuwstelsel zijn gemyelineerd. Axonen met 
een kleinere diameter dan 1 µm zijn weliswaar geassocieerd met Schwann cellen, 
maar ze worden niet gemyelineerd. Het is niet bekend hoe de axonen Schwann 
cellen kunnen instrueren voor de aanleg of het niet aanlegen van de myeline schede. 
Het is wel bekend dat beschadiging of instabiliteit van de myeline schede leidt tot 
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een verslechterde geleiding van signalen langs deze zenuwbanen. Dit resulteert in 
ernstige neurologische problemen. Bekende voorbeelden van ziektes waarbij de 
myeline schede is aangedaan zijn onder andere de auto-immuun ziektes multiple 
sclerose (MS) en Guillain-Barré of de genetische afwijkingen Charcot-Marie-Tooth 
(CMT), Dejerine Sottas en Perlizaeus-Merzbacher.
Er is aangetoond dat een tijdige aanwezigheid van het Oct-6 eiwit in 
Schwann cellen belangrijk is voor het tijdig vormen van de myeline schede. Een van 
de centrale vragen in dit proefschrift is hoe het Oct-6 gen wordt gereguleerd om 
op het juiste moment in Schwann cellen actief te zijn. Voorafgaande experimenten 
binnen onze onderzoeksgroep hebben laten zien dat binnen enige afstand van het 
Oct-6 gen een gebied van 4000 base paren (bp), genaamd de Oct-6 Schwann Cell 
Enhancer (SCE), belangrijk is voor de expressie van het Oct-6 gen. Dit element is in 
staat om een reporter gen (dat een zichtbare blauwe kleur kan vormen) in Schwann 
cellen tot expressie te brengen in dezelfde periode en met hetzelfde patroon van 
het Oct-6 gen. Dit suggereert dat de expressie van het Oct-6 gen in Schwann cellen 
gecontroleerd wordt door dit element.
De proeven beschreven in hoofdstuk 2, laten zien dat de SCE inderdaad 
het regulerende element is voor de aanwezigheid van het Oct-6 eiwit op het juiste 
moment in Schwann cellen maar niet in andere type cellen waar Oct-6 wel tot 
expressie komt. Tevens is de SCE ook betrokken bij expressie van het Oct-6 gen 
tijdens regeneratie. Dit maakt de SCE aantrekkelijk met het oog op de ontwikkeling 
van toekomstige therapieën in ziektes die ontstaan door een defect gen in de 
Schwann cellen.
In hoofdstuk 3, hebben wij verder gezocht welk gedeelte binnen de SCE 
belangrijk is voor het binden van transcriptie factoren die vervolgens het Oct-6 
gen expressie in Schwann cellen op tijd kunnen aan- en uitschakelen. Voor deze 
proeven hebben we drie verschillende benaderingen gekozen. Als eerste hebben 
we de DNA sequentie van de SCE in muizen vergeleken met die van de mens en 
de rat in een specifiek computer programma. Aangezien de sequentie van genen en 
de belangrijke regulator elementen tijdens de evolutie geconserveerd zijn gebleven, 
is het mogelijk dat een geconserveerde regio binnen de SCE sequentie op zulke 
elementen duiden. Binnen de SCE hebben we inderdaad twee zeer geconserveerde 
regios gevonden, genaamd HR1 en HR2. Verder hebben we de functie van deze 
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twee regios getest in onze gekweekte Schwann cellen met gebruik van een in vitro 
(op een schaal) experiment en in transgene muizen (in vivo). Met deze experimenten 
hebben we laten zien dat HR1 en HR2 belangrijke sequenties bevatten voor het 
binden van transcriptie factoren, die vervolgens het Oct-6 gen activeren. Verder 
hebben we verschillende deletie constructen gemaakt door de steeds weglaten 
van 500 base paren van de SCE sequentie in een construct inclusief een reporter 
gen. Vervolgens konden we de activiteit van deze deletie constructen in onze 
gekweekte Schwann cellen testen door te kijken naar de expressie van het reporter 
gen Uit deze proeven zijn twee regios naar voren gekomen die belangrijk zijn voor 
de activiteit van het reporter gen. Deze twee regios vallen binnen de voorgaande 
geïdentificeerde HR1 en HR2. Vervolgens hebben we de functie van deze twee 
kleinere fragmenten getest in transgene muizen en geconcludeerd dat deze twee 
regio samen nodig zijn voor de expressie van het Oct-6 gen in Schwann cellen. 
In gewervelde dieren vormen Schwann cellen de myeline schede na de 
geboorte. Voorafgaande experimenten binnen onze groep en andere groepen 
hebben aangetoond dat de Oct-6 transcriptie factor belangrijk is voor de juiste 
timing van de aanleg van de myeline schede. In afwezigheid van het Oct-6 eiwit 
in een proefdier model, zoals de muis, wordt de myeline schede met twee weken 
vertraging gevormd. Hier ontstaat de vraag waarom in afwezigheid van Oct-
6, Schwann cellen uiteindelijk alsnog de myeline schede kunnen aanleggen. Het 
is aannemelijk dat een ander eiwit in Schwann cellen aanwezig is die de functie 
van het Oct-6 eiwit kan overnemen. De experimenten die in hoofdstuk 4 staan 
beschreven hebben aangetoond dat een andere eiwit, Brn-2, inderdaad na enige tijd 
de functie van Oct-6 in de Schwann cellen overneemt. Wij hebben laten zien dat een 
verhoogde expressie van het Brn-2 eiwit in Schwann cellen van een muis met een 
defect Oct-6 gen, de Schwann cellen gedeeltelijk eerder beginnen met de myeline 
aanleg vergeleken met Oct-6 deficiënte Schwann cellen. Verder, het inactief maken 
van het Oct-6 en het Brn-2 gen in Schwann cellen van muizen met behulp van 
genetische technieken (homologe recombinatie) leidt tot veel ernstigere effecten 
op Schwann cellen; zelfs na 3 maanden is de formatie van de myeline schede niet 
compleet. Dit experiment laat zien dat Brn-2 inderdaad de functie van Oct-6 in 
Schwann cellen kan overnemen. 
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In het laatste hoofdstuk bediscussiëren we verschillende signalering routes 
die kunnen leiden tot Schwann cellen een myelinerende lot nemen.
Aan de hand van een model suggereren we hoe de geïdentificeerde HR1a 
en HR2b elementen op DNA niveau de Oct-6 gen expressie kunnen reguleren. 
Vervolgens hebben we verschillende vervolg-experimenten besproken voor het 
voorzetten van dit onderzoek.
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Dankwoord
Eindelijk ben ik dan zover; de laatste pagina van mijn boekje. Een heleboel 
dingen kan ik over de afgelopen jaren vertellen. De barbecue traditie van het lab in 
de afgelopen jaren, de Oct-6 dag, …
Dit proefschrift is natuurlijk niet alleen mijn werk, maar mede gevormd door 
en met de hulp van een heleboel mensen. Als eerste wil ik mijn promotor Prof. 
Frank Grosveld bedanken. Beste Frank, de werkbesprekingen in de zithoek samen 
met je kritische vragen en opmerkingen vond ik altijd heel leuk en leerzaam. Mijn 
grote dank gaat uit naar mijn co-promotor Dies Meijer. Dies, ik ben altijd onder de 
indruk van je enthousiasme voor de wetenschap en je kennis, zowel praktisch als 
theoretisch. Ik waardeer ontzettend dat je deur altijd voor mij open stond en dat je 
altijd tijd vrij kon maken om mijn vele vragen te beantwoorden. Je heb me enorm 
geholpen met het ordenen van mijn gedachten tijdens het schrijven. 
Vervolgens de mensen van de Oct-6 groep: Martine, Wim, Marko, Aysel, 
Smiriti, Siska, Matthijs, Nardus en Arend. Wim, door jou ben ik op weg geholpen 
in het SCE project. Jij hebt me met heel veel enthousiasme jouw werk en ideeën 
uitgelegd in het begin van mijn AIO-tijd. Toen je voor je post-doc naar de USA 
ging heb ik je heel erg gemist. Ik wens je heel veel succes in je toekomstige carrière; 
vooral met afronden van je onderzoek en terugkomen naar Nederland. Marko, with 
you we never know when we will see you next time. Your presence was always 
appreciated because of the discussions and suggestions for future experiments and 
your practical tips. I wish you a lot of success in your career wherever you are and 
good luck with defending your thesis in near future. Smiriti, ondanks de korte 
periode dat je bij ons hebt gewerkt, wil ik je bedanken voor je hulp en gezelligheid 
op lab 1075. Aysel, we zijn ongeveer tegelijkertijd begonnen met onze AIO-periode 
bij Dies. Ik wens je hierbij alvast heel veel succes met de verdediging van je 
proefschrift. Siska, over jou kan ik een boek schrijven. Je aanwezigheid in het lab 
bracht altijd heel veel gezelligheid; je muziekkeuze werd niet altijd gewaardeerd, 
maar soms toch stiekem wel. Je bent altijd bereid om op het lab met de praktische 
dingen te helpen. Bedankt voor het doorlezen van mijn proefschrift om spelfouten 
te verwijderen. PS wil je voortaan van de Cola afblijven. Matthijs, in het laatste jaar 
van mijn AIO periode heb ik met jou op het lab gewerkt. Bedankt voor je hulp tijdens 
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drukke tijden met veel proeven. Ik vraag me af welk t-shirt je aandoet voor het 
promotiefeest. Arend, je bent altijd bereid geweest me uit de computerproblemen 
te helpen. Bedankt voor de figuren! Het was leuk om met jou over mijn proeven of 
het schrijven te praten. Nardus, succes met je promotieonderzoek. Ook Jacqueline 
en Dorota bedankt voor de gezelligheid in de laatste jaar. 
Natuurlijk wil ik ook de mensen van het lab 1075 noemen bij wie ik heb 
gewerkt: Sjaak, Nienke, Roy, Rita, Fokke, PF, Robert, Peter. Bedankt voor gezellige 
tijden. Sjaak bedankt voor kritisch lezen van het manuscript. Ik vind je hamburgers 
ook erg lekker. Beste Nienke, jij was de allereerste bij wie ik met mijn problemen 
terechtkon. Zelfs in de laatste periode toen je al verhuisd was naar de 6de rende 
ik vaak (en graag) naar beneden voor mijn vele praktische problemen met mijn 
experimenten en voor het kwijt raken van alle frustratie voor de  proeven die niet 
lukten. Jouw geweldige eigenschap om je ervaring te delen met anderen waardeer 
ik heel erg. Daarnaast hebben we een mooie vriendschap opgebouwd. Roy en 
Rita, onze fantasieën tijdens het borrelen over een tripelpromotie zijn waarheid 
geworden! 27 oktober; wat een spannende dag voor ons alledrie. 
Van het lab 1002 wil ik ook graag mensen noemen voor de gezellige tijden: 
Claudia, Katrin, Kirsty, Catherine, Charles, Aneta and Karin. Elein, thank you 
for your advises, support and your encouraging words during my dark/weak 
periods.
In de afgelopen jaren, hebben ook veel mensen mij buiten het lab geholpen: 
Niels bedankt voor kritisch lezen van het manuscript en leuke gespreken met je, 
Pim wil ik je bedanken voor de mooie EM plaatjes en je latere hulp bij al mijn 
computerproblemen. Ook wil ik graag Ton en Sjozef en Leo bedanken voor jullie 
hulp op computergebied. John Kong-a-San voor het doen van de micro-injecties en 
je geduld toen je het mij leerde. Ton de Wit voor al je hulp, Marike, Rita, Jasperina; 
bedankt voor jullie snelle hulp elke keer als ik binnen kwam rennen. Ook de 
fotografen (jullie hebben ooit eens een opa en oma in Iran heel blij gemaakt), de 
dames van de spoelkeuken, de mensen van het EDC en alle andere dat ik niet bij 
naam heb genoemd, allen bedankt!
Dan, mijn paranimfen: Beste Martine, jij bent een bijzondere collega, en een 
trouwe vriendin. Jouw steun gedurende de vijf jaar dat ik samen met jou op het 
lab gewerkt, beteken heel veel voor me. Beste Ellen, je bent mijn maatje. Je heb me 
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gesteund vanaf het begin van onze biologiestudie aan de VU. Bedankt voor al je 
hulp, steun, interesse in mijn werk. Het is ontzettend leuk om samen onze twee 
knulletjes voor een uitje mee te nemen. Jullie zijn perfecte paranimfen en ik vind 
het een eer om tijdens de verdediging naast jullie te staan.
Tot slot wil ik mijn familie en vrienden bedanken voor jullie belangstelling 
in mijn onderzoek: 
mijn broer en zus, Mehrdad en Mehrzad voor jullie support en aandacht, 
Aram, Fahime, Masoud, Ydo (je heb me gered met je enorm hulp bij de lay-out), 
Bep en Joop voor een altijd warme ontvangst en gezelligheid bij jullie thuis.
En als laatste natuurlijk mijn beste vriend en levens partner, Saeed. Je bent 
mijn dag- en nachtsteun geweest vanaf onze eerste ontmoeting. Bedankt, voor al 
de weekenden en nachten die je samen met mij doorgebracht eerst op de VU, dan 
het NKI, en later hier, voor al de picknicken, voor al de keren dat je Arian hier heeft 
gebracht om hem even bij mij hebben, voor je zorg, voor al de momenten dat je mij 
gerust kon stelen en voor je oneindige begrip en je geduld met mij. Hierna gaan we 
wat rustiger doen en meer samen genieten van Arian.
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